UA116187C2 - ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ - Google Patents
ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИInfo
- Publication number
- UA116187C2 UA116187C2 UAA201115478A UAA201115478A UA116187C2 UA 116187 C2 UA116187 C2 UA 116187C2 UA A201115478 A UAA201115478 A UA A201115478A UA A201115478 A UAA201115478 A UA A201115478A UA 116187 C2 UA116187 C2 UA 116187C2
- Authority
- UA
- Ukraine
- Prior art keywords
- pyrrolo
- pyridines
- pyrimidines
- janus kinase
- kinase inhibitors
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
- A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0014—Skin, i.e. galenical aspects of topical compositions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/04—Antipruritics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
- C07B59/002—Heterocyclic compounds
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
- C07B2200/00—Indexing scheme relating to specific properties of organic compounds
- C07B2200/05—Isotopically modified compounds, e.g. labelled
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Oncology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US74990505P | 2005-12-13 | 2005-12-13 | |
| US81023106P | 2006-06-02 | 2006-06-02 | |
| US85062506P | 2006-10-10 | 2006-10-10 | |
| US85687206P | 2006-11-03 | 2006-11-03 | |
| US85940406P | 2006-11-16 | 2006-11-16 | |
| UAA200809072A UA98449C2 (en) | 2005-12-13 | 2006-12-12 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| UA116187C2 true UA116187C2 (uk) | 2018-02-26 |
Family
ID=37903501
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200809072A UA98449C2 (en) | 2005-12-13 | 2006-12-12 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| UAA201115478A UA116187C2 (uk) | 2005-12-13 | 2006-12-12 | ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| UAA200809072A UA98449C2 (en) | 2005-12-13 | 2006-12-12 | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
Country Status (36)
Families Citing this family (441)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20060106020A1 (en) * | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| EP1928874A1 (en) * | 2005-09-16 | 2008-06-11 | AstraZeneca AB | Heterobicyclic compounds as glucokinase activators |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| US8604042B2 (en) * | 2005-11-01 | 2013-12-10 | Targegen, Inc. | Bi-aryl meta-pyrimidine inhibitors of kinases |
| US8133900B2 (en) * | 2005-11-01 | 2012-03-13 | Targegen, Inc. | Use of bi-aryl meta-pyrimidine inhibitors of kinases |
| JP5191391B2 (ja) * | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| SG10202003901UA (en) | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| EA200870117A1 (ru) * | 2005-12-23 | 2008-12-30 | Смитклайн Бичам Корпорейшн | Азаиндоловые ингибиторы аурора-киназ |
| PL2003132T3 (pl) * | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| SG170828A1 (en) * | 2006-04-05 | 2011-05-30 | Vertex Pharmaceuticals Inc Us | Deazapurines useful as inhibitors of janus kinases |
| AU2007322033B2 (en) | 2006-11-20 | 2013-07-11 | President And Fellows Of Harvard College | Methods, compositions, and kits for treating pain and pruritis |
| CA2673038C (en) * | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
| KR20150036210A (ko) * | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CL2008001709A1 (es) * | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| CA2692379A1 (en) * | 2007-07-02 | 2009-01-08 | Boehringer Ingelheim International Gmbh | Antiproliferative compounds based on 5-membered heterocycles |
| WO2009032338A1 (en) * | 2007-09-09 | 2009-03-12 | University Of Florida Research Foundation | Apratoxin therapeutic agents: mechanism and methods of treatment |
| WO2009049028A1 (en) * | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| EP2211620B1 (en) * | 2007-10-25 | 2013-12-25 | Merck Sharp & Dohme Corp. | 3-PYRAZIN SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AS JANUS KINASE INHIBITORS FOR THE TREATMENT OF CANCER DISEASES |
| UA104849C2 (uk) * | 2007-11-16 | 2014-03-25 | Інсайт Корпорейшн | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus |
| PE20091485A1 (es) * | 2008-02-06 | 2009-10-26 | Novartis Ag | DERIVADOS DE PIRROLO-[2,3-d]-PIRIMIDINA COMO INHIBIDORES DE CINASAS |
| WO2009114552A1 (en) * | 2008-03-10 | 2009-09-17 | The Board Of Trustees Of The Leland Stanford Junior University | Heteroaryl compounds, compositions, and methods of use in cancer treatment |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| EP2278969B1 (en) * | 2008-04-21 | 2013-02-13 | Merck Sharp & Dohme Corp. | Inhibitors of Janus kinases |
| EP2274288A2 (en) * | 2008-04-24 | 2011-01-19 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| CL2009001152A1 (es) | 2008-05-13 | 2009-10-16 | Array Biopharma Inc | Compuestos derivados de n-(4-(cicloalquilo nitrogenado-1-il)-1h-pirrolo[2,3-b]piridin-3-il)amida, inhibidores de cinasa; proceso de preparacion; composicion farmaceutica; y su uso para el tratamiento de una enfermedad proliferativa. |
| EP2299816B1 (en) * | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| WO2009155565A1 (en) * | 2008-06-20 | 2009-12-23 | Genentech, Inc. | Triazolopyridine jak inhibitor compounds and methods |
| CN102131389A (zh) * | 2008-06-20 | 2011-07-20 | 健泰科生物技术公司 | 三唑并吡啶jak抑制剂化合物和方法 |
| CL2009001884A1 (es) * | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| AT507187B1 (de) | 2008-10-23 | 2010-03-15 | Helmut Dr Buchberger | Inhalator |
| TWI720517B (zh) * | 2009-01-15 | 2021-03-01 | 美商英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| WO2010085597A1 (en) * | 2009-01-23 | 2010-07-29 | Incyte Corporation | Macrocyclic compounds and their use as kinase inhibitors |
| SI2432472T1 (sl) * | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| AR076794A1 (es) * | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| ES2540964T3 (es) | 2009-06-08 | 2015-07-15 | Takeda Pharmaceutical Company Limited | Compuestos de dihidropirrolonaftiridinona como inhibidores de JAK |
| KR101763656B1 (ko) | 2009-06-29 | 2017-08-01 | 인사이트 홀딩스 코포레이션 | Ｐｉ3ｋ 저해물질로서의 피리미디논 |
| JP6205133B2 (ja) | 2009-07-10 | 2017-09-27 | プレジデント アンド フェローズ オブ ハーバード カレッジ | 抗炎症剤としての恒久的に荷電したナトリウムおよびカルシウムチャンネルブロッカー |
| TWI466885B (zh) | 2009-07-31 | 2015-01-01 | Japan Tobacco Inc | 含氮螺環化合物及其醫藥用途 |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| EP2485589A4 (en) * | 2009-09-04 | 2013-02-06 | Biogen Idec Inc | HETEROARYL-BTK INHIBITORS |
| JP5658756B2 (ja) | 2009-09-10 | 2015-01-28 | エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ | Ｊａｋの阻害剤 |
| EP2482815B1 (en) | 2009-10-02 | 2018-05-02 | Avexxin AS | Antiinflammatory 2-oxothiazoles and 2-oxooxazoles |
| EA021478B1 (ru) * | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| US8389728B2 (en) * | 2009-11-06 | 2013-03-05 | The Arizona Board Of Regents | Pollen tube stimulants from Arabidopsis pistils |
| JP5858434B2 (ja) * | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
| WO2011109217A2 (en) * | 2010-03-02 | 2011-09-09 | Immunodiagnostics, Inc. | Methods of treating or preventing rna polymerase dependent viral disorders by administration of jak2 kinase inhibitors |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| AU2015205858B2 (en) * | 2010-03-10 | 2017-04-13 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| KR20130094710A (ko) * | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| AR081626A1 (es) | 2010-04-23 | 2012-10-10 | Cytokinetics Inc | Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos |
| US9133123B2 (en) | 2010-04-23 | 2015-09-15 | Cytokinetics, Inc. | Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use |
| AR081331A1 (es) | 2010-04-23 | 2012-08-08 | Cytokinetics Inc | Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| KR101541086B1 (ko) * | 2010-08-20 | 2015-08-03 | 허치슨 메디파르마 리미티드 | 피롤로피리미딘 화합물 및 그 용도 |
| WO2012040527A2 (en) * | 2010-09-24 | 2012-03-29 | The Regents Of The University Of Michigan | Deubiquitinase inhibitors and methods for use of the same |
| US9056855B2 (en) | 2010-10-28 | 2015-06-16 | Viamet Pharmaceuticals, Inc. | Metalloenzyme inhibitor compounds |
| AU2010363329A1 (en) | 2010-11-07 | 2013-05-09 | Targegen, Inc. | Compositions and methods for treating myelofibrosis |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (es) * | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| EA036970B1 (ru) * | 2010-11-19 | 2021-01-21 | Инсайт Холдингс Корпорейшн | Применение {1-{1-[3-фтор-2-(трифтометил)изоникотиноил] пиперидин-4-ил}-3-[4-(7h-пирроло[2,3-d]пиримидин-4-ил)-1н-пиразол-1-ил]азетидин-3-ил}ацетонитрила для лечения заболеваний, связанных с активностью jak1 |
| JP6097998B2 (ja) * | 2010-12-16 | 2017-03-22 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | ロイコトリエン生成のビアリールアミドインヒビター |
| EP3660016A1 (en) | 2010-12-20 | 2020-06-03 | Incyte Holdings Corporation | N-(1-(substituted-phenyl)ethyl)-9h-purin-6-amines as pi3k inhibitors |
| CA2824970C (en) | 2011-02-11 | 2016-05-03 | Batmark Limited | Inhaler component |
| ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| AR085392A1 (es) * | 2011-02-24 | 2013-09-25 | Cephalon Inc | Compuestos de azufre aromaticos sustituidos y metodos para su uso en el tratamiento y prevencion del cancer |
| CN103547580B (zh) | 2011-03-22 | 2016-12-07 | 阿迪维纳斯疗法有限公司 | 取代的稠合三环化合物、其组合物及医药用途 |
| US8759380B2 (en) | 2011-04-22 | 2014-06-24 | Cytokinetics, Inc. | Certain heterocycles, compositions thereof, and methods for their use |
| CN103502249A (zh) * | 2011-05-17 | 2014-01-08 | 普林斯匹亚生物制药公司 | 作为酪氨酸激酶抑制剂的氮杂吲哚衍生物 |
| PH12013502523A1 (en) | 2011-06-14 | 2019-10-11 | Novartis Ag | Combination of panobinostat and ruxolitinib in the treatment of cancer such as a myeloproliferative neoplasm |
| CN103797010B (zh) * | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| ES2548414T3 (es) | 2011-07-08 | 2015-10-16 | Novartis Ag | Novedosos derivados de pirrolo pirimidina |
| EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| PT3513793T (pt) | 2011-09-02 | 2021-05-10 | Incyte Holdings Corp | Heterociclilaminas como inibidores de pi3k |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| CA2849168A1 (en) | 2011-09-22 | 2013-03-28 | Merck Sharp & Dohme Corp. | Cycloalkylnitrile pyrazole carboxamides as janus kinase inhibitors |
| CN103987713A (zh) * | 2011-10-12 | 2014-08-13 | 阵列生物制药公司 | 5,7-取代的咪唑并[1,2-c]嘧啶 |
| ES3018133T3 (en) | 2011-11-30 | 2025-05-14 | Univ Emory | Jak inhibitors for use in the prevention or treatment of a viral disease caused by a coronaviridae |
| US10821111B2 (en) | 2011-11-30 | 2020-11-03 | Emory University | Antiviral JAK inhibitors useful in treating or preventing retroviral and other viral infections |
| EP2788000B1 (en) * | 2011-12-06 | 2018-05-30 | Merck Sharp & Dohme Corp. | Pyrrolopyrimidines as janus kinase inhibitors |
| AR090548A1 (es) | 2012-04-02 | 2014-11-19 | Incyte Corp | Azaheterociclobencilaminas biciclicas como inhibidores de pi3k |
| WO2013173506A2 (en) | 2012-05-16 | 2013-11-21 | Rigel Pharmaceuticals, Inc. | Method of treating muscular degradation |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| HRP20250965T1 (hr) | 2012-06-15 | 2025-10-10 | Sun Pharmaceutical Industries, Inc. | Deuterirani derivati ruksolitiniba |
| JP6280546B2 (ja) | 2012-06-26 | 2018-02-14 | デル マー ファーマシューティカルズ | ジアンヒドロガラクチトール、ジアセチルジアンヒドロガラクチトール、ジブロモズルシトール、又はこれらの類似体若しくは誘導体を用いた、遺伝子多型又はａｈｉ１の調節不全若しくは変異を有する患者におけるチロシンキナーゼインヒビター抵抗性悪性腫瘍を処置するための方法 |
| US20150246043A1 (en) * | 2012-07-27 | 2015-09-03 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| BR112015002152B1 (pt) | 2012-08-02 | 2021-04-27 | Nerviano Medical Sciences S.R.L. | Compostos de pirróis substituídos ativos como inibidores de quinases, processo para a preparação de tais compostos, composição farmacêutica, método in vitro para a inibição da atividade de proteínas quinases da família jak e produto compreendendo os referidos compostos |
| US9593115B2 (en) | 2012-09-21 | 2017-03-14 | Advinus Therapeutics Ltd. | Substituted fused tricyclic compounds, compositions, and medicinal applications thereof |
| KR20150060839A (ko) * | 2012-10-26 | 2015-06-03 | 에프. 호프만-라 로슈 아게 | 브루톤 티로신 키나아제의 억제제 |
| TWI646099B (zh) | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| US9310374B2 (en) | 2012-11-16 | 2016-04-12 | Redwood Bioscience, Inc. | Hydrazinyl-indole compounds and methods for producing a conjugate |
| US10130632B2 (en) | 2012-11-27 | 2018-11-20 | Beth Israel Deaconess Medical Center, Inc. | Methods for treating renal disease |
| WO2014089296A2 (en) * | 2012-12-06 | 2014-06-12 | Institute For Hepatitis And Virus Research | Functionalized benzamide derivatives as antiviral agents against hbv infection |
| US9260426B2 (en) * | 2012-12-14 | 2016-02-16 | Arrien Pharmaceuticals Llc | Substituted 1H-pyrrolo [2, 3-b] pyridine and 1H-pyrazolo [3, 4-b] pyridine derivatives as salt inducible kinase 2 (SIK2) inhibitors |
| EP2951164B1 (en) | 2013-01-29 | 2019-06-05 | Avexxin AS | Antiinflammatory and antitumor 2-oxothiazoles compounds |
| WO2014124280A1 (en) | 2013-02-08 | 2014-08-14 | Institute For Myeloma & Bone Cancer Research | Improved diagnostic, prognostic, and monitoring methods for multiple myeloma, chronic lymphocytic leukemia, and b-cell non-hodgkin lymphoma |
| US20150380681A1 (en) * | 2013-02-12 | 2015-12-31 | Konica Minolta, Inc. | Organic electroluminescent element and lighting device |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| US20140343034A1 (en) | 2013-04-25 | 2014-11-20 | Japan Tobacco Inc. | Skin barrier function improving agent |
| HUE033587T2 (hu) | 2013-05-17 | 2017-12-28 | Incyte Corp | Bipirazol-származékok mint JAK inhibitorok |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| CA2921568A1 (en) * | 2013-08-20 | 2015-02-25 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| WO2015048312A1 (en) | 2013-09-26 | 2015-04-02 | Costim Pharmaceuticals Inc. | Methods for treating hematologic cancers |
| US9611263B2 (en) | 2013-10-08 | 2017-04-04 | Calcimedica, Inc. | Compounds that modulate intracellular calcium |
| CN105636962B (zh) * | 2013-10-15 | 2017-10-13 | 靳博涵 | 新型化合物、用途及其制备方法 |
| MX2016006894A (es) | 2013-11-27 | 2016-08-17 | Novartis Ag | Terapia de combinacion que comprende un inhibidor de jak, cdk y pim. |
| SI3077395T1 (en) | 2013-12-05 | 2018-03-30 | Pfizer Inc. | Pyrrolo(2,3-d)pyrimidinyl, pyrrolo(2,3-b)pyrazinyl and pyrrolo(2,3-d)pyridinyl acrylamides |
| JP6367545B2 (ja) * | 2013-12-17 | 2018-08-01 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| CN110229159B (zh) * | 2013-12-18 | 2021-08-24 | 康塞特医药品有限公司 | 卢索替尼的氘代衍生物 |
| KR102261733B1 (ko) * | 2013-12-18 | 2021-06-04 | 콘서트 파마슈티컬즈, 인크. | 룩소리티닙의 중수소화된 유도체 |
| PE20170255A1 (es) | 2014-01-24 | 2017-03-22 | Dana Farber Cancer Inst Inc | Moleculas de anticuerpo que se unen a pd-1 y usos de las mismas |
| HUE045065T2 (hu) | 2014-01-31 | 2019-12-30 | Novartis Ag | TIM-3 antitest molekulák és felhasználásaik |
| WO2015131080A1 (en) | 2014-02-28 | 2015-09-03 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| KR20160136323A (ko) | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| KR102442436B1 (ko) | 2014-03-14 | 2022-09-15 | 노파르티스 아게 | Lag-3에 대한 항체 분자 및 그의 용도 |
| SI3129021T1 (sl) | 2014-04-08 | 2021-07-30 | Incyte Corporation | Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| RU2564891C1 (ru) * | 2014-05-27 | 2015-10-10 | Александр Александрович Кролевец | Способ получения нанокапсул цитокининов |
| WO2015184087A2 (en) * | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| CN105218548A (zh) * | 2014-06-09 | 2016-01-06 | 上海海和药物研究开发有限公司 | 一种新型杂环化合物及其制备方法和作为激酶抑制剂的用途 |
| WO2015191677A1 (en) | 2014-06-11 | 2015-12-17 | Incyte Corporation | Bicyclic heteroarylaminoalkyl phenyl derivatives as pi3k inhibitors |
| NZ629796A (en) * | 2014-07-14 | 2015-12-24 | Signal Pharm Llc | Amorphous form of 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d]oxazol-6-yl)-7h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| WO2016010886A1 (en) * | 2014-07-14 | 2016-01-21 | Signal Pharmaceuticals, Llc | Methods of treating a cancer using substituted pyrrolopyrimidine compounds, compositions thereof |
| GB201413695D0 (en) | 2014-08-01 | 2014-09-17 | Avexxin As | Compound |
| AR101504A1 (es) | 2014-08-11 | 2016-12-21 | Acerta Pharma Bv | Combinaciones terapéuticas de un inhibidor de la btk, un inhibidor de la pi3k, un inhibidor de la jak-2, y/o un inhibidor de la cdk4/6 |
| TW201618775A (zh) | 2014-08-11 | 2016-06-01 | 艾森塔製藥公司 | Ｂｔｋ抑制劑、ｐｉ３ｋ抑制劑、ｊａｋ－２抑制劑、ｐｄ－１抑制劑及／或ｐｄ－ｌ１抑制劑之治療組合物 |
| PL3179991T3 (pl) | 2014-08-11 | 2022-02-14 | Acerta Pharma B.V. | Kombinacje terapeutyczne inhibitora btk i inhibitora bcl-2 |
| CN117088931A (zh) | 2014-08-12 | 2023-11-21 | 莫纳什大学 | 定向淋巴的前药 |
| EP3183252B1 (en) * | 2014-08-21 | 2021-05-12 | ratiopharm GmbH | Oxalate salt of ruxolitinib |
| KR20170060042A (ko) | 2014-09-13 | 2017-05-31 | 노파르티스 아게 | Alk 억제제의 조합 요법 |
| CN105524067A (zh) * | 2014-09-28 | 2016-04-27 | 江苏柯菲平医药股份有限公司 | 4-取代吡咯并[2,3-d]嘧啶化合物及其用途 |
| KR20170066546A (ko) | 2014-10-03 | 2017-06-14 | 노파르티스 아게 | 조합 요법 |
| MA41044A (fr) | 2014-10-08 | 2017-08-15 | Novartis Ag | Compositions et procédés d'utilisation pour une réponse immunitaire accrue et traitement contre le cancer |
| EP4245376A3 (en) | 2014-10-14 | 2023-12-13 | Novartis AG | Antibody molecules to pd-l1 and uses thereof |
| WO2016063294A2 (en) * | 2014-10-20 | 2016-04-28 | Msn Laboratories Private Limited | Process for the preparation of (r)-3-(4-(7h-pyrrolo[2,3-d], pyrimidin-4-yl)-1 h-pyrazol-1-yl)-3-cyclopentylpropanenitrile phosphate and its polymorphs thereof |
| CN107148425B (zh) | 2014-10-29 | 2021-08-03 | 拜斯科阿迪有限公司 | 对mt1-mmp特异性的双环肽配体 |
| GB2535427A (en) | 2014-11-07 | 2016-08-24 | Nicoventures Holdings Ltd | Solution |
| CZ2014773A3 (cs) | 2014-11-10 | 2016-05-18 | Zentiva, K.S. | Soli (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu |
| CN105777754B (zh) * | 2014-12-16 | 2019-07-26 | 北京赛林泰医药技术有限公司 | 吡咯并嘧啶化合物 |
| SG10201907576SA (en) | 2015-02-27 | 2019-09-27 | Incyte Corp | Salts of pi3k inhibitor and processes for their preparation |
| TWI788655B (zh) | 2015-02-27 | 2023-01-01 | 美商林伯士拉克許米公司 | 酪胺酸蛋白質激酶2(tyk2)抑制劑及其用途 |
| EA035817B1 (ru) | 2015-03-10 | 2020-08-14 | Адуро Байотек, Инк. | Композиции и способы для активации сигналинга, зависимого от "гена стимулятора интерферона" |
| KR101859170B1 (ko) * | 2015-04-17 | 2018-05-17 | 광주과학기술원 | 트리아졸 화합물 및 이의 용도 |
| AU2016254385B2 (en) * | 2015-04-29 | 2018-05-10 | Wuxi Fortune Pharmaceutical Co., Ltd | JAK inhibitors |
| US9840503B2 (en) | 2015-05-11 | 2017-12-12 | Incyte Corporation | Heterocyclic compounds and uses thereof |
| US9732097B2 (en) | 2015-05-11 | 2017-08-15 | Incyte Corporation | Process for the synthesis of a phosphoinositide 3-kinase inhibitor |
| US9988401B2 (en) | 2015-05-11 | 2018-06-05 | Incyte Corporation | Crystalline forms of a PI3K inhibitor |
| WO2017004134A1 (en) | 2015-06-29 | 2017-01-05 | Nimbus Iris, Inc. | Irak inhibitors and uses thereof |
| CZ2015496A3 (cs) | 2015-07-14 | 2017-01-25 | Zentiva, K.S. | Krystalické formy solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a jejich příprava |
| WO2017011720A1 (en) * | 2015-07-16 | 2017-01-19 | Signal Pharmaceuticals, Llc | Solod forms 4-((4-(cyclopentyloxy)-5-(2-methylbenzo[d] oxazol-6-yl)17h-pyrrolo[2,3-d]pyrimidin-2-yl)amino)-3-methoxy-n-methylbenzamide, compositions thereof and methods of their use |
| EP3878465A1 (en) | 2015-07-29 | 2021-09-15 | Novartis AG | Combination therapies comprising antibody molecules to tim-3 |
| EP3328418A1 (en) | 2015-07-29 | 2018-06-06 | Novartis AG | Combination therapies comprising antibody molecules to pd-1 |
| HRP20211058T8 (hr) | 2015-07-29 | 2021-11-26 | Novartis Ag | Kombinirane terapije koje sadrže molekule antitijela protiv lag-3 |
| KR20180069782A (ko) | 2015-08-03 | 2018-06-25 | 프레지던트 앤드 펠로우즈 오브 하바드 칼리지 | 하전 이온 채널 블록커 및 이용 방법 |
| US9708333B2 (en) | 2015-08-12 | 2017-07-18 | Incyte Corporation | Fused bicyclic 1,2,4-triazine compounds as TAM inhibitors |
| WO2017035366A1 (en) * | 2015-08-26 | 2017-03-02 | Incyte Corporation | Pyrrolopyrimidine derivatives as tam inhibitors |
| TWI707852B (zh) | 2015-09-02 | 2020-10-21 | 美商林伯士拉克許米公司 | Tyk2 抑制劑及其用途 |
| US11738087B2 (en) | 2015-09-08 | 2023-08-29 | Monash University | Lymph directing prodrugs |
| US10683308B2 (en) | 2015-09-11 | 2020-06-16 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| GB2542838B (en) | 2015-10-01 | 2022-01-12 | Nicoventures Trading Ltd | Aerosol provision system |
| AU2016342027B2 (en) | 2015-10-23 | 2021-05-13 | Navitor Pharmaceuticals, Inc. | Modulators of Sestrin-GATOR2 interaction and uses thereof |
| PE20181326A1 (es) | 2015-11-03 | 2018-08-20 | Janssen Biotech Inc | Anticuerpos que se unen especificamente a pd-1 y sus usos |
| PT3371190T (pt) | 2015-11-06 | 2022-07-08 | Incyte Corp | Compostos heterocíclicos como inibidores de pi3k-gamma |
| EP3373937B1 (en) | 2015-11-09 | 2021-12-22 | R.P. Scherer Technologies, LLC | Anti-cd22 antibody-maytansine conjugates and methods of use thereof |
| RU2601410C1 (ru) * | 2015-11-13 | 2016-11-10 | ЗАО "Р-Фарм" | {3-[(7H-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)АЗОЛИЛ]АЗЕТИДИН-3-ИЛ}АЦЕТОНИТРИЛЫ В КАЧЕСТВЕ ИНГИБИТОРОВ ЯНУС КИНАЗ |
| EP3389664A4 (en) | 2015-12-14 | 2020-01-08 | Raze Therapeutics Inc. | MTHFD2 CAFFEIN INHIBITORS AND USES THEREOF |
| CN108368115B (zh) * | 2015-12-15 | 2020-01-03 | 正大天晴药业集团股份有限公司 | 吡咯并嘧啶化合物的盐 |
| US20200261573A1 (en) | 2015-12-17 | 2020-08-20 | Novartis Ag | Combination of c-met inhibitor with antibody molecule to pd-1 and uses thereof |
| ES2986067T3 (es) | 2015-12-17 | 2024-11-08 | Novartis Ag | Moléculas de anticuerpos frente a PD-1 y usos de las mismas |
| US9630968B1 (en) | 2015-12-23 | 2017-04-25 | Arqule, Inc. | Tetrahydropyranyl amino-pyrrolopyrimidinone and methods of use thereof |
| US10562904B2 (en) | 2015-12-31 | 2020-02-18 | Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Synthesis process of ruxolitinib |
| ES2898329T3 (es) | 2016-01-12 | 2022-03-07 | Oncotracker Inc | Métodos mejorados para supervisar el estado inmunitario de un sujeto |
| CZ201629A3 (cs) | 2016-01-22 | 2017-08-02 | Zentiva, K.S. | Krystalické modifikace solí (3R)-3-cyklopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propannitrilu a způsoby jejich přípravy |
| CN106905322B (zh) * | 2016-01-26 | 2019-10-15 | 杭州华东医药集团新药研究院有限公司 | 吡咯嘧啶五元氮杂环衍生物及其应用 |
| CN105541891B (zh) * | 2016-02-04 | 2017-11-28 | 东南大学 | 巴瑞替尼的中间体及其制备方法及由该中间体制备巴瑞替尼的方法 |
| DK3426243T3 (da) | 2016-03-09 | 2021-07-19 | Raze Therapeutics Inc | 3-phosphoglyceratdehydrogenase-inhibitorer og anvendelser deraf |
| EP4234552A3 (en) | 2016-03-09 | 2023-10-18 | Raze Therapeutics, Inc. | 3-phosphoglycerate dehydrogenase inhibitors and uses thereof |
| GB201604318D0 (en) | 2016-03-14 | 2016-04-27 | Avexxin As | Combination therapy |
| KR102483020B1 (ko) | 2016-03-28 | 2023-01-04 | 인사이트 코포레이션 | Tam 저해제로서의 피롤로트리아진 화합물 |
| CA3019394A1 (en) | 2016-04-08 | 2017-10-12 | X4 Pharmaceuticals, Inc. | Methods for treating cancer |
| ES2988629T3 (es) | 2016-05-04 | 2024-11-21 | Sun Pharmaceutical Ind Inc | Tratamiento de trastornos de pérdida de cabello con inhibidores de JAK deuterados |
| MX394560B (es) | 2016-06-01 | 2025-03-24 | Bayer Pharma AG | Uso de indazoles sustituidos para el tratamiento y la prevencion de enfermedades en animales. |
| CN107513067A (zh) * | 2016-06-16 | 2017-12-26 | 北京赛林泰医药技术有限公司 | 含有取代环戊基的吡咯并嘧啶化合物 |
| CN107513069A (zh) * | 2016-06-16 | 2017-12-26 | 正大天晴药业集团股份有限公司 | 手性吡咯并嘧啶化合物的制备方法 |
| CN107759600A (zh) * | 2016-06-16 | 2018-03-06 | 正大天晴药业集团股份有限公司 | 作为jak抑制剂的吡咯并嘧啶化合物的结晶 |
| ES2870920T3 (es) | 2016-06-21 | 2021-10-28 | X4 Pharmaceuticals Inc | Inhibidores de CXCR4 y usos de los mismos |
| CN109640988A (zh) | 2016-06-21 | 2019-04-16 | X4 制药有限公司 | Cxcr4抑制剂及其用途 |
| EP3472129A4 (en) | 2016-06-21 | 2019-12-04 | X4 Pharmaceuticals, Inc. | CXCR4 INHIBITORS AND USES THEREOF |
| MX388591B (es) | 2016-06-30 | 2025-03-20 | Daewoong Pharmaceutical Co Ltd | Derivados de pirazolopirimidina como inhibidor de cinasa. |
| EP3507367A4 (en) | 2016-07-05 | 2020-03-25 | Aduro BioTech, Inc. | CYCLIC DINUCLEOTID COMPOUNDS WITH INCLUDED NUCLEIC ACIDS AND USES THEREOF |
| KR102598246B1 (ko) * | 2016-07-26 | 2023-11-02 | 톈진 롱보진 파마시우티컬 씨오., 엘티디. | Jak 저해제로서 헤테로사이클릭 화합물, 및 이의 염 및 치료학적 용도 |
| TW201811795A (zh) | 2016-08-24 | 2018-04-01 | 美商亞闊股份有限公司 | 胺基－吡咯并嘧啶酮化合物及其用途 |
| JOP20190024A1 (ar) | 2016-08-26 | 2019-02-19 | Gilead Sciences Inc | مركبات بيروليزين بها استبدال واستخداماتها |
| IT201600092051A1 (it) * | 2016-09-13 | 2018-03-13 | Alessandro Antonelli | Composto medicale per il trattamento di tumori della tiroide |
| US10323036B2 (en) | 2016-10-14 | 2019-06-18 | Nimbus Lakshmi, Inc. | TYK2 inhibitors and uses thereof |
| EP3528816A4 (en) | 2016-10-21 | 2020-04-08 | Nimbus Lakshmi, Inc. | TYK2 INHIBITORS AND USES THEREOF |
| WO2018089499A1 (en) | 2016-11-08 | 2018-05-17 | Navitor Pharmaceuticals, Inc. | PHENYL AMINO PIPERIDINE mTORC INHIBITORS AND USES THEREOF |
| CA3043768A1 (en) | 2016-11-29 | 2018-06-07 | PureTech Health LLC | Exosomes for delivery of therapeutic agents |
| US11091451B2 (en) | 2016-12-05 | 2021-08-17 | Raze Therapeutics, Inc. | SHMT inhibitors and uses thereof |
| RU2644155C1 (ru) * | 2016-12-12 | 2018-02-08 | Закрытое акционерное общество "Р-Фарм" (ЗАО "Р-Фарм") | 2-(3-(4-(7H-пирроло[2,3-d]пиримидин-4-ил)-1H-пиразол-1-ил)-1-(этилсульфонил)азетидин-3-ил)ацетонитрила геминафтилдисульфонат в качестве ингибитора Янус киназ |
| WO2018115203A1 (en) | 2016-12-23 | 2018-06-28 | Bicyclerd Limited | Peptide derivatives having novel linkage structures |
| US10624968B2 (en) | 2017-01-06 | 2020-04-21 | Bicyclerd Limited | Compounds for treating cancer |
| EA039352B1 (ru) * | 2017-01-19 | 2022-01-17 | Сучжоу Лонгбайотек Фармасьютикалз Ко., Лтд. | Соединение в качестве селективного ингибитора jak и его соли и терапевтическое применение |
| TW202515876A (zh) | 2017-03-08 | 2025-04-16 | 日商武田藥品工業股份有限公司 | Tyk2抑制劑及其用途 |
| EP3375784A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aza-dihydro-acridone derivatives |
| EP3375778A1 (en) | 2017-03-14 | 2018-09-19 | Artax Biopharma Inc. | Aryl-piperidine derivatives |
| WO2018191146A1 (en) | 2017-04-10 | 2018-10-18 | Navitor Pharmaceuticals, Inc. | Heteroaryl rheb inhibitors and uses thereof |
| JOP20180036A1 (ar) | 2017-04-18 | 2019-01-30 | Vifor Int Ag | أملاح لمثبطات فروبورتين جديدة |
| PL3615019T3 (pl) | 2017-04-26 | 2026-01-19 | Navitor Pharmaceuticals, Inc. | Modulator interakcji sestryna-gator2 do zastosowania w leczeniu depresji opornej na leczenie |
| US10857196B2 (en) | 2017-04-27 | 2020-12-08 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| UY37695A (es) | 2017-04-28 | 2018-11-30 | Novartis Ag | Compuesto dinucleótido cíclico bis 2’-5’-rr-(3’f-a)(3’f-a) y usos del mismo |
| PH12019502605A1 (en) | 2017-05-23 | 2020-10-26 | Theravance Biopharma R&D Ip Llc | Glucuronide prodrugs of janus kinase inhibitors |
| US11635435B2 (en) | 2017-06-13 | 2023-04-25 | Oncotracker, Inc. | Diagnostic, prognostic, and monitoring methods for solid tumor cancers |
| MY204117A (en) | 2017-06-22 | 2024-08-08 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| EP3642240A1 (en) | 2017-06-22 | 2020-04-29 | Novartis AG | Antibody molecules to cd73 and uses thereof |
| EP3645549A1 (en) | 2017-06-26 | 2020-05-06 | BicycleRD Limited | Bicyclic peptide ligands with detectable moieties and uses thereof |
| CN107298680A (zh) * | 2017-07-12 | 2017-10-27 | 海门华祥医药科技有限公司 | 一种4‑氯‑7‑氮杂吲哚的生产工艺 |
| SI3658557T1 (sl) | 2017-07-28 | 2024-10-30 | Takeda Pharmaceutical Company Limited | Zaviralci TYK2 in njihova uporaba |
| JP7670481B2 (ja) | 2017-08-04 | 2025-04-30 | バイスクルテクス・リミテッド | Ｃｄ１３７に対して特異的な二環式ペプチドリガンド |
| WO2019034866A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | BICYCLIC PEPTIDE LIGANDS CONJUGATES AND USES THEREOF |
| WO2019034868A1 (en) | 2017-08-14 | 2019-02-21 | Bicyclerd Limited | CONJUGATES PEPTIDE BICYCLIC-LIGAND PPR-A AND USES THEREOF |
| US11883497B2 (en) | 2017-08-29 | 2024-01-30 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| CA3077739A1 (en) | 2017-08-29 | 2019-03-07 | Puretech Lyt, Inc. | Lymphatic system-directing lipid prodrugs |
| WO2019060742A1 (en) | 2017-09-22 | 2019-03-28 | Kymera Therapeutics, Inc | AGENTS FOR DEGRADING PROTEINS AND USES THEREOF |
| US11358948B2 (en) | 2017-09-22 | 2022-06-14 | Kymera Therapeutics, Inc. | CRBN ligands and uses thereof |
| MA50655B1 (fr) | 2017-09-27 | 2021-11-30 | Incyte Corp | Sels de dérivés de pyrrolotriazine utiles en tant qu'inhibiteurs de tam |
| CN109651424B (zh) * | 2017-10-11 | 2021-01-22 | 新发药业有限公司 | 一种7-保护基-4-(1-氢-吡唑-4-基)吡咯[2,3-d]嘧啶的合成方法 |
| WO2019090143A1 (en) * | 2017-11-03 | 2019-05-09 | Aclaris Therapeutics, Inc. | Pyrazolyl pyrrolo[2,3-b]pyrimidine-5-carboxylate analogs and methods of making the same |
| KR102821964B1 (ko) | 2017-11-03 | 2025-06-19 | 어클라리스 쎄라퓨틱스, 인코포레이티드 | 치환된 피롤로피리미딘 jak 억제제 및 이의 제조 및 사용 방법 |
| KR102034538B1 (ko) | 2017-11-28 | 2019-10-21 | 주식회사한국파마 | Jak 저해제 화합물, 및 이의 제조방법 |
| WO2019113487A1 (en) | 2017-12-08 | 2019-06-13 | Incyte Corporation | Low dose combination therapy for treatment of myeloproliferative neoplasms |
| US11304954B2 (en) | 2017-12-19 | 2022-04-19 | Puretech Lyt, Inc. | Lipid prodrugs of mycophenolic acid and uses thereof |
| EP3727362A4 (en) | 2017-12-19 | 2021-10-06 | PureTech LYT, Inc. | MYCOPHENOLIC ACID LIPID PRODRUGS AND THEIR USES |
| US11608345B1 (en) | 2017-12-19 | 2023-03-21 | Puretech Lyt, Inc. | Lipid prodrugs of rapamycin and its analogs and uses thereof |
| TWI825046B (zh) | 2017-12-19 | 2023-12-11 | 英商拜西可泰克斯有限公司 | Epha2特用之雙環胜肽配位基 |
| GB201721265D0 (en) | 2017-12-19 | 2018-01-31 | Bicyclerd Ltd | Bicyclic peptide ligands specific for EphA2 |
| IL315310A (en) | 2017-12-26 | 2024-10-01 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2019140380A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| WO2019140387A1 (en) | 2018-01-12 | 2019-07-18 | Kymera Therapeutics, Inc. | Crbn ligands and uses thereof |
| US12398209B2 (en) | 2018-01-22 | 2025-08-26 | Janssen Biotech, Inc. | Methods of treating cancers with antagonistic anti-PD-1 antibodies |
| JP7229257B2 (ja) | 2018-01-29 | 2023-02-28 | メルク パテント ゲーエムベーハー | Ｇｃｎ２阻害剤およびその使用 |
| BR112020015396A2 (pt) | 2018-01-29 | 2020-12-08 | Merck Patent Gmbh | Inididores de gcn2 e usos dos mesmos |
| SG11202007164UA (en) | 2018-01-30 | 2020-08-28 | Incyte Corp | Processes for preparing (1 -(3-fluoro-2-(trifluoromethyl)isonicotinyl)piperidine-4-one) |
| KR102925957B1 (ko) | 2018-02-16 | 2026-02-11 | 인사이트 코포레이션 | 사이토카인-관련 장애의 치료를 위한 jak1 경로 억제제 |
| CN111902429A (zh) | 2018-02-23 | 2020-11-06 | 拜斯科技术开发有限公司 | 多聚体双环肽配体 |
| JP7050165B2 (ja) | 2018-02-26 | 2022-04-07 | ギリアード サイエンシーズ， インコーポレイテッド | Ｈｂｖ複製阻害剤としての置換ピロリジン化合物 |
| EP3759086A1 (en) | 2018-02-27 | 2021-01-06 | Artax Biopharma Inc. | Chromene derivatives as inhibitors of tcr-nck interaction |
| CA3092931A1 (en) | 2018-03-08 | 2019-09-12 | Novartis Ag | Use of an anti-p-selectin antibody |
| CN110357887B (zh) * | 2018-03-26 | 2022-09-16 | 武汉誉祥医药科技有限公司 | 取代的7H-吡咯并[2,3-d]嘧啶衍生物及其制备方法和用途 |
| MA52655A (fr) | 2018-03-30 | 2021-02-17 | Incyte Corp | Biomarqueurs pour maladie cutanée inflammatoire |
| SMT202400306T1 (it) | 2018-03-30 | 2024-09-16 | Incyte Corp | Trattamento dell'idrosadenite suppurativa utilizzando inibitori di jak. |
| CA3097025A1 (en) | 2018-04-13 | 2019-10-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| ES2969982T3 (es) | 2018-04-24 | 2024-05-23 | Vertex Pharma | Compuestos de pteridinona y usos de los mismos |
| HRP20241163T1 (hr) | 2018-04-24 | 2024-11-22 | Merck Patent Gmbh | Antiproliferacijski spojevi i njihova uporaba |
| TWI869346B (zh) | 2018-05-30 | 2025-01-11 | 瑞士商諾華公司 | Ｅｎｔｐｄ２抗體、組合療法、及使用該等抗體和組合療法之方法 |
| WO2019232244A2 (en) | 2018-05-31 | 2019-12-05 | Novartis Ag | Antibody molecules to cd73 and uses thereof |
| SG11202011680YA (en) | 2018-06-01 | 2020-12-30 | Incyte Corp | Dosing regimen for the treatment of pi3k related disorders |
| EP3805219A4 (en) * | 2018-06-06 | 2022-03-23 | Gengle Therapeutics, Inc. | PYRAZOLOPYRIMIDI DERIVATIVE, ITS USE AND PHARMACEUTICAL COMPOSITION |
| WO2019241789A1 (en) | 2018-06-15 | 2019-12-19 | Navitor Pharmaceuticals, Inc. | Rapamycin analogs and uses thereof |
| IL279489B2 (en) | 2018-06-22 | 2025-10-01 | Bicycletx Ltd | Bicyclic peptide ligands specific for nectin-4, a drug conjugate containing the peptide ligands and a pharmaceutical composition containing the drug conjugate |
| GB201810316D0 (en) | 2018-06-22 | 2018-08-08 | Bicyclerd Ltd | Peptide ligands for binding to EphA2 |
| AR117600A1 (es) | 2018-06-29 | 2021-08-18 | Incyte Corp | Formulaciones de un inhibidor de axl / mer |
| JP6830460B2 (ja) * | 2018-07-05 | 2021-02-17 | コンサート ファーマシューティカルズ インコーポレイテッド | ルキソリチニブの重水素化誘導体 |
| WO2020010177A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Tricyclic crbn ligands and uses thereof |
| WO2020010227A1 (en) | 2018-07-06 | 2020-01-09 | Kymera Therapeutics, Inc. | Protein degraders and uses thereof |
| CN117285467A (zh) | 2018-07-31 | 2023-12-26 | 罗索肿瘤学公司 | 喷雾干燥的分散体和制剂 |
| CN119080779A (zh) | 2018-08-10 | 2024-12-06 | 阿克拉瑞斯治疗股份有限公司 | 吡咯并嘧啶itk抑制剂 |
| WO2020039401A1 (en) | 2018-08-24 | 2020-02-27 | Novartis Ag | Treatment comprising il-1βeta binding antibodies and combinations thereof |
| US10548889B1 (en) | 2018-08-31 | 2020-02-04 | X4 Pharmaceuticals, Inc. | Compositions of CXCR4 inhibitors and methods of preparation and use |
| WO2020051424A1 (en) | 2018-09-07 | 2020-03-12 | Pic Therapeutics | Eif4e inhibitors and uses thereof |
| CN113271940A (zh) | 2018-10-15 | 2021-08-17 | 林伯士拉克许米公司 | Tyk2抑制剂和其用途 |
| WO2020084305A1 (en) | 2018-10-23 | 2020-04-30 | Bicycletx Limited | Bicyclic peptide ligands and uses thereof |
| EP3870158A4 (en) | 2018-10-24 | 2022-08-10 | Navitor Pharmaceuticals, Inc. | Polymorphic compounds and uses thereof |
| CA3117969A1 (en) | 2018-10-31 | 2020-05-07 | Incyte Corporation | Combination therapy for treatment of hematological diseases |
| CA3120866A1 (en) | 2018-11-30 | 2020-06-04 | Nimbus Lakshmi, Inc. | Tyk2 inhibitors and uses thereof |
| CA3119773A1 (en) | 2018-11-30 | 2020-06-04 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN109394768B (zh) * | 2018-12-10 | 2019-08-23 | 牡丹江医学院 | 一种治疗湿疹的药物及其制备方法 |
| GB201820295D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for MT1-MMP |
| GB201820325D0 (en) | 2018-12-13 | 2019-01-30 | Bicyclerd Ltd | Bicyclic peptide ligands specific for psma |
| GB201820288D0 (en) | 2018-12-13 | 2019-01-30 | Bicycle Tx Ltd | Bicycle peptide ligaands specific for MT1-MMP |
| CN111320633B (zh) * | 2018-12-14 | 2022-09-27 | 中国医药研究开发中心有限公司 | 吡咯/咪唑并六元杂芳环类化合物及其制备方法和医药用途 |
| US12351571B2 (en) | 2018-12-19 | 2025-07-08 | Array Biopharma Inc. | Substituted quinoxaline compounds as inhibitors of FGFR tyrosine kinases |
| EP3898626A1 (en) | 2018-12-19 | 2021-10-27 | Array Biopharma, Inc. | Substituted pyrazolo[1,5-a]pyridine compounds as inhibitors of fgfr tyrosine kinases |
| EP3670659A1 (en) | 2018-12-20 | 2020-06-24 | Abivax | Biomarkers, and uses in treatment of viral infections, inflammations, or cancer |
| US20220040324A1 (en) | 2018-12-21 | 2022-02-10 | Daiichi Sankyo Company, Limited | Combination of antibody-drug conjugate and kinase inhibitor |
| WO2020128527A1 (en) | 2018-12-21 | 2020-06-25 | Bicyclerd Limited | Bicyclic peptide ligands specific for pd-l1 |
| US12492224B2 (en) | 2018-12-21 | 2025-12-09 | Bicycletx Limited | Bicyclic peptide ligands specific for PD-L1 |
| CN113348021B (zh) | 2019-01-23 | 2025-07-11 | 武田药品工业株式会社 | Tyk2抑制剂和其用途 |
| WO2020165600A1 (en) | 2019-02-14 | 2020-08-20 | Bicycletx Limited | Bicyclic peptide ligand sting conjugates and uses thereof |
| CN111620873B (zh) * | 2019-02-28 | 2021-12-28 | 沈阳药科大学 | 一类含哌啶的吡咯并[2,3-d]嘧啶衍生物及其制备和用途 |
| WO2020181034A1 (en) | 2019-03-05 | 2020-09-10 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of chronic lung allograft dysfunction |
| AU2020235888A1 (en) | 2019-03-11 | 2021-09-30 | Nocion Therapeutics, Inc. | Charged ION channel blockers and methods for use |
| US10828287B2 (en) | 2019-03-11 | 2020-11-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| MX2021010869A (es) | 2019-03-11 | 2022-01-19 | Nocion Therapeutics Inc | Bloqueadores de canales iónicos sustituidos por éster y métodos para su uso. |
| US10934263B2 (en) | 2019-03-11 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US10780083B1 (en) | 2019-03-11 | 2020-09-22 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| US11624751B2 (en) | 2019-03-19 | 2023-04-11 | Incyte Corporation | Biomarkers for vitiligo |
| EA202192575A1 (ru) | 2019-03-21 | 2022-01-14 | Онксео | Соединения dbait в сочетании с ингибиторами киназ для лечения рака |
| SG11202110828UA (en) | 2019-04-02 | 2021-10-28 | Bicycletx Ltd | Bicycle toxin conjugates and uses thereof |
| CN120574283A (zh) | 2019-04-05 | 2025-09-02 | 凯麦拉医疗公司 | Stat降解剂和其用途 |
| US11548895B2 (en) | 2019-04-24 | 2023-01-10 | Elanco Us Inc. | Process for making crystalline 2-(3-(4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1H-pyrazol-1-yl)-1-(cyclopropylsulfonyl)azetidin-3-yl)acetonitrile |
| CA3138544A1 (en) | 2019-05-02 | 2020-11-05 | Aclaris Therapeutics, Inc. | Substituted pyrrolopyridines as jak inhibitors |
| KR102286372B1 (ko) | 2019-05-27 | 2021-08-05 | 주식회사한국파마 | Jak 저해제 화합물, 및 이를 포함하는 의약 조성물 |
| CN110028509B (zh) * | 2019-05-27 | 2020-10-09 | 上海勋和医药科技有限公司 | 作为选择性jak2抑制剂的吡咯并嘧啶类化合物、其合成方法及用途 |
| AU2020284742B2 (en) * | 2019-05-28 | 2026-03-05 | Mankind Pharma Ltd. | Novel compounds for inhibition of Janus Kinase 1 |
| CA3141826A1 (en) | 2019-05-31 | 2020-12-03 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| JP7532511B2 (ja) | 2019-06-10 | 2024-08-13 | インサイト・コーポレイション | Ｊａｋ阻害剤による尋常性白斑の局所治療 |
| WO2020251972A1 (en) | 2019-06-10 | 2020-12-17 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2020261219A1 (en) | 2019-06-27 | 2020-12-30 | Crispr Therapeutics Ag | Use of chimeric antigen receptor t cells and nk cell inhibitors for treating cancer |
| PH12022500002A1 (en) | 2019-06-28 | 2023-04-03 | Kymera Therapeutics Inc | Irak degraders and uses thereof |
| WO2021011868A1 (en) | 2019-07-17 | 2021-01-21 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| CN110305140B (zh) | 2019-07-30 | 2020-08-04 | 上海勋和医药科技有限公司 | 二氢吡咯并嘧啶类选择性jak2抑制剂 |
| TWI860386B (zh) | 2019-07-30 | 2024-11-01 | 英商拜西可泰克斯有限公司 | 異質雙環肽複合物 |
| US20220235043A1 (en) * | 2019-07-31 | 2022-07-28 | Aclaris Therapeutics, Inc. | Substituted sulfonamide pyrrolopyridines as jak inhibitors |
| WO2021022076A1 (en) * | 2019-08-01 | 2021-02-04 | St. Jude Children's Research Hospital | Molecules and methods related to treatment of uncontrolled cellular proliferation |
| US11845724B2 (en) | 2019-09-11 | 2023-12-19 | Vincere Biosciences, Inc. | USP30 inhibitors and uses thereof |
| MX2022002877A (es) | 2019-09-13 | 2022-08-08 | Nimbus Saturn Inc | Antagonistas de cinasa progenitora hematopoyetica 1 (hpk1) y sus usos. |
| WO2021053490A1 (en) | 2019-09-16 | 2021-03-25 | Novartis Ag | Use of high-affinity, ligand-blocking, humanized anti-t-cell immunoglobulin domain and mucin domain-3 (tim-3) igg4 antibody for the treatment of myelofibrosis |
| BR112022004225A2 (pt) | 2019-09-16 | 2022-05-31 | Novartis Ag | Uso de um inibidor de mdm2 para o tratamento de mielofibrose |
| CN114502590A (zh) | 2019-09-18 | 2022-05-13 | 诺华股份有限公司 | Entpd2抗体、组合疗法、以及使用这些抗体和组合疗法的方法 |
| US20220372135A1 (en) | 2019-09-27 | 2022-11-24 | Disc Medicine, Inc. | Methods for treating myelofibrosis and related conditions |
| CN110538183B (zh) * | 2019-10-09 | 2021-05-04 | 吉林大学 | 一种预防和治疗小儿湿疹的组合物及其制备方法 |
| WO2021072098A1 (en) | 2019-10-10 | 2021-04-15 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| EP4041204A1 (en) | 2019-10-10 | 2022-08-17 | Incyte Corporation | Biomarkers for graft-versus-host disease |
| JP7518900B2 (ja) | 2019-10-16 | 2024-07-18 | インサイト・コーポレイション | 皮膚エリテマトーデス及び扁平苔癬（ｌｐ）の治療のためのｊａｋ１阻害剤の使用 |
| US11992490B2 (en) | 2019-10-16 | 2024-05-28 | Incyte Corporation | Use of JAK1 inhibitors for the treatment of cutaneous lupus erythematosus and Lichen planus (LP) |
| US11723890B2 (en) | 2019-11-01 | 2023-08-15 | Navitor Pharmaceuticals, Inc. | Methods of treatment using an mTORC1 modulator |
| CN114828845A (zh) | 2019-11-06 | 2022-07-29 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| US10933055B1 (en) | 2019-11-06 | 2021-03-02 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN114761006A (zh) | 2019-11-08 | 2022-07-15 | Inserm(法国国家健康医学研究院) | 对激酶抑制剂产生耐药性的癌症的治疗方法 |
| JP7717065B2 (ja) | 2019-11-22 | 2025-08-01 | インサイト コーポレーション | Ａｌｋ２阻害剤及びｊａｋ２阻害剤を含む併用療法 |
| AU2020397938A1 (en) | 2019-12-05 | 2022-06-23 | Janssen Pharmaceutica Nv | Rapamycin analogs and uses thereof |
| WO2021119159A1 (en) | 2019-12-10 | 2021-06-17 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| KR20220145325A (ko) | 2019-12-17 | 2022-10-28 | 카이메라 쎄라퓨틱스 인코포레이티드 | Irak 분해제 및 이의 용도 |
| EP4076524A4 (en) | 2019-12-17 | 2023-11-29 | Kymera Therapeutics, Inc. | IRAQ DEGRADERS AND USES THEREOF |
| EP4081308A4 (en) | 2019-12-23 | 2024-01-24 | Kymera Therapeutics, Inc. | Smarca degraders and uses thereof |
| WO2021133917A1 (en) | 2019-12-23 | 2021-07-01 | Kymera Therapeutics, Inc. | Smarca inhibitors and uses thereof |
| CN115210229A (zh) | 2020-01-03 | 2022-10-18 | 博格有限责任公司 | 多环酰胺作为治疗癌症的ube2k调节剂 |
| WO2021148581A1 (en) | 2020-01-22 | 2021-07-29 | Onxeo | Novel dbait molecule and its use |
| IL295362A (en) | 2020-02-05 | 2022-10-01 | Puretech Lyt Inc | Lipid drug inhibitors of neurosteroids |
| CN111728975A (zh) * | 2020-02-25 | 2020-10-02 | 广东省检迅检测科技有限公司 | 用于减少运动损伤和促进运动损伤修复的组合物 |
| TW202146393A (zh) | 2020-03-03 | 2021-12-16 | 美商皮克醫療公司 | Eif4e抑制劑及其用途 |
| WO2021178779A1 (en) | 2020-03-06 | 2021-09-10 | Incyte Corporation | Combination therapy comprising axl/mer and pd-1/pd-l1 inhibitors |
| US12162851B2 (en) | 2020-03-11 | 2024-12-10 | Nocion Therapeutics, Inc. | Charged ion channel blockers and methods for use |
| CN119118953A (zh) | 2020-03-11 | 2024-12-13 | 诺西恩医疗公司 | 带电的离子通道阻滞剂及其使用方法 |
| KR20230005160A (ko) | 2020-03-19 | 2023-01-09 | 카이메라 쎄라퓨틱스 인코포레이티드 | Mdm2 분해제 및 이의 용도 |
| US11324750B2 (en) | 2020-04-09 | 2022-05-10 | Children's Hospital Medical Center | Compositions and methods for the treatment of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection |
| WO2021206766A1 (en) | 2020-04-09 | 2021-10-14 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| EP3892280A3 (en) | 2020-04-09 | 2022-01-12 | Children's Hospital Medical Center | Sars-cov-2 infection biomarkers and uses thereof |
| US20230218644A1 (en) | 2020-04-16 | 2023-07-13 | Som Innovation Biotech, S.A. | Compounds for use in the treatment of viral infections by respiratory syndrome-related coronavirus |
| KR20230012539A (ko) | 2020-05-13 | 2023-01-26 | 디스크 메디슨, 인크. | 골수섬유증을 치료하기 위한 항-헤모주벨린 (hjv) 항체 |
| WO2021236139A1 (en) | 2020-05-21 | 2021-11-25 | Concert Pharmaceuticals, Inc. | Novel deuterated jak inhibitor and uses thereof |
| MX2022015221A (es) | 2020-06-02 | 2023-03-08 | Incyte Corp | Procesos para preparar un inhibidor de cinasa jano 1 (jak1). |
| TW202210483A (zh) | 2020-06-03 | 2022-03-16 | 美商凱麥拉醫療公司 | Irak降解劑之結晶型 |
| US11833155B2 (en) | 2020-06-03 | 2023-12-05 | Incyte Corporation | Combination therapy for treatment of myeloproliferative neoplasms |
| US20230250110A1 (en) | 2020-06-03 | 2023-08-10 | Kymera Therapeutics, Inc. | Deuterated irak degraders and uses thereof |
| PT4161528T (pt) | 2020-06-03 | 2026-01-23 | Incyte Corp | Combinação de ruxolitinib com incb057643 para utilização no tratamento de neoplasias mieloproliferativas |
| US11345681B1 (en) | 2020-06-05 | 2022-05-31 | Kinnate Biopharma Inc. | Inhibitors of fibroblast growth factor receptor kinases |
| WO2021260657A1 (en) | 2020-06-26 | 2021-12-30 | Crispr Therapeutics Ag | Allogeneic cell therapy of b cell malignancies using genetically engineered t cells targeting cd19 |
| EP3944859A1 (en) | 2020-07-30 | 2022-02-02 | Assistance Publique Hôpitaux de Paris | Method for treating immune toxicities induced by immune checkpoint inhibitors |
| AU2021322934A1 (en) | 2020-08-03 | 2023-03-30 | Bicycletx Limited | Peptide-based linkers |
| US11751108B2 (en) * | 2020-08-05 | 2023-09-05 | Qualcomm Incorporated | Execution of reduced signaling handover |
| CA3194469A1 (en) * | 2020-08-12 | 2022-02-17 | Concert Pharmaceuticals, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
| CA3186504A1 (en) | 2020-08-17 | 2022-02-24 | Stephen J. Blakemore | Bicycle conjugates specific for nectin-4 and uses thereof |
| PE20231743A1 (es) | 2020-08-18 | 2023-10-31 | Incyte Corp | Proceso e intermediarios para preparar un inhibidor de jak |
| IL300557A (en) | 2020-08-18 | 2023-04-01 | Incyte Corp | Process and intermediates for preparing a JAK1 inhibitor |
| WO2022061351A1 (en) | 2020-09-16 | 2022-03-24 | Incyte Corporation | Topical treatment of vitiligo |
| WO2022060094A1 (ko) * | 2020-09-16 | 2022-03-24 | 주식회사 엑세쏘바이오파마 | 피리미도 피리미디논 화합물 및 그를 포함하는 약제학적 조성물 |
| EP4221711A1 (en) | 2020-10-02 | 2023-08-09 | Incyte Corporation | Topical ruxolitinib for treating lichen planus |
| EP4225317A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| EP4225316A1 (en) | 2020-10-08 | 2023-08-16 | Novartis AG | Use of an erk inhibitor for the treatment of myelofibrosis |
| US12331046B2 (en) | 2020-10-23 | 2025-06-17 | Nimbus Clotho, Inc. | CTPS1 inhibitors and uses thereof |
| CN114437079B (zh) * | 2020-10-30 | 2024-11-01 | 杭州邦顺制药有限公司 | 吡咯嘧啶五元氮杂环化合物的晶型 |
| KR102551758B1 (ko) | 2020-11-30 | 2023-07-05 | 주식회사한국파마 | 신규한 jak 특이 저해제 화합물, 및 이의 제조방법 |
| WO2022120353A1 (en) | 2020-12-02 | 2022-06-09 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CA3200814A1 (en) | 2020-12-02 | 2022-06-09 | Alfredo C. Castro | Tead inhibitors and uses thereof |
| HUE071614T2 (hu) | 2020-12-04 | 2025-09-28 | Incyte Corp | JAK-inhibitor D-vitamin-analóggal bõrbetegségek kezelésére |
| CA3204374A1 (en) | 2020-12-08 | 2022-06-16 | Incyte Corporation | Jak1 pathway inhibitors for the treatment of vitiligo |
| EP4259144A4 (en) | 2020-12-09 | 2025-08-20 | Kymera Therapeutics Inc | SMARCA DEGRADING AGENTS AND THEIR USES |
| MX2023007150A (es) | 2020-12-18 | 2023-09-04 | Boehringer Ingelheim Animal Health Usa Inc | Compuestos de pirazol que contienen boro, composiciones que los comprenden, métodos y usos de los mismos. |
| CN116867758A (zh) | 2020-12-30 | 2023-10-10 | 凯麦拉医疗公司 | Irak降解剂和其用途 |
| TW202237083A (zh) | 2021-01-11 | 2022-10-01 | 美商英塞特公司 | 包含ｊａｋ路徑抑制劑及ｒｏｃｋ抑制劑之組合療法 |
| US20240174662A1 (en) * | 2021-02-01 | 2024-05-30 | Janssen Biotech, Inc. | Small molecule inhibitors of salt inducible kinases |
| MX2023009060A (es) | 2021-02-02 | 2023-09-29 | Liminal Biosciences Ltd | Antagonistas de gpr84 y usos de estos. |
| US12378229B2 (en) | 2021-02-02 | 2025-08-05 | Liminal Biosciences Limited | GPR84 antagonists and uses thereof |
| WO2022166796A1 (zh) * | 2021-02-05 | 2022-08-11 | 上海齐鲁制药研究中心有限公司 | 嘧啶或吡啶并杂环类腺苷受体抑制剂及其制备方法和用途 |
| EP4291235A4 (en) | 2021-02-12 | 2025-01-08 | Nimbus Saturn, Inc. | HPK1 ANTAGONISTS AND USES THEREOF |
| US12171768B2 (en) | 2021-02-15 | 2024-12-24 | Kymera Therapeutics, Inc. | IRAK4 degraders and uses thereof |
| CN116867494A (zh) | 2021-02-15 | 2023-10-10 | 凯麦拉医疗公司 | Irak4降解剂和其用途 |
| MX2023009858A (es) | 2021-02-25 | 2023-09-12 | Impact Biomedicines Inc | Uso de inhibidores de proteina de bromodominio y motivo extraterminal (bet) solo o en combinacion con fedratinib o ruxolitinib como tratamiento para una malignidad hematologica tal como la mielofibrosis. |
| US11926625B2 (en) | 2021-03-05 | 2024-03-12 | Nimbus Saturn, Inc. | HPK1 antagonists and uses thereof |
| WO2022213062A1 (en) | 2021-03-29 | 2022-10-06 | Nimbus Saturn, Inc. | Hpk1 antagonists and uses thereof |
| US12325697B2 (en) | 2021-04-09 | 2025-06-10 | Nimbus Clio, Inc. | CBL-B modulators and uses thereof |
| WO2022221866A1 (en) | 2021-04-16 | 2022-10-20 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| UA129643C2 (uk) | 2021-05-03 | 2025-06-18 | Інсайт Корпорейшн | Інгібітори шляху jak1 для лікування вузлуватого свербця |
| KR20240020735A (ko) | 2021-05-07 | 2024-02-15 | 카이메라 쎄라퓨틱스 인코포레이티드 | Cdk2 분해제 및 그 용도 |
| US12071439B2 (en) | 2021-07-12 | 2024-08-27 | Incyte Corporation | Process and intermediates for preparing a JAK inhibitor |
| CA3228505A1 (en) | 2021-08-11 | 2023-02-16 | Sun Pharmaceutical Industries, Inc. | Treatment of hair loss disorders with deuterated jak inhibitors |
| CA3229560A1 (en) | 2021-08-25 | 2023-03-02 | Christopher L. Vandeusen | Eif4e inhibitors and uses thereof |
| US12157732B2 (en) | 2021-08-25 | 2024-12-03 | PIC Therapeutics, Inc. | eIF4E inhibitors and uses thereof |
| KR102718345B1 (ko) * | 2021-09-16 | 2024-10-17 | 광주과학기술원 | 신규한 트리아졸릴피롤로피리미딘 유도체 및 이의 용도 |
| CA3231996A1 (en) * | 2021-09-18 | 2023-03-23 | Satya Srinivas HANUMARA | An improved process for the preparation of ruxolitinib phosphate |
| EP4423086A1 (en) | 2021-10-25 | 2024-09-04 | Kymera Therapeutics, Inc. | Tyk2 degraders and uses thereof |
| CA3236265A1 (en) | 2021-10-29 | 2023-05-04 | William Leong | Irak4 degraders and synthesis thereof |
| US12290565B2 (en) | 2021-11-17 | 2025-05-06 | Altrubio Inc. | Methods of using anti-PSGL-1 antibodies in combination with JAK inhibitors to treat T-cell mediated inflammatory diseases or cancers |
| WO2023102559A1 (en) | 2021-12-03 | 2023-06-08 | Incyte Corporation | Topical formulations of ruxolitinib with an organic amine ph adjusting agent for treatment of skin diseases |
| WO2023114984A1 (en) | 2021-12-17 | 2023-06-22 | Ikena Oncology, Inc. | Tead inhibitors and uses thereof |
| CN114044777B (zh) * | 2022-01-10 | 2022-04-19 | 南京佰麦生物技术有限公司 | 一种磷酸芦可替尼的制备方法 |
| CA3243560A1 (en) | 2022-01-31 | 2023-08-03 | Kymera Therapeutics, Inc. | Iraqi Degradation Agents and Their Uses |
| CN114456181A (zh) * | 2022-02-21 | 2022-05-10 | 浙江乐普药业股份有限公司 | 一种芦可替尼的制备方法 |
| WO2023173057A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023173053A1 (en) | 2022-03-10 | 2023-09-14 | Ikena Oncology, Inc. | Mek inhibitors and uses thereof |
| WO2023211889A1 (en) | 2022-04-25 | 2023-11-02 | Ikena Oncology, Inc. | Polymorphic compounds and uses thereof |
| US11878958B2 (en) | 2022-05-25 | 2024-01-23 | Ikena Oncology, Inc. | MEK inhibitors and uses thereof |
| AU2023293093A1 (en) * | 2022-06-14 | 2025-01-02 | Incyte Corporation | Solid forms of a jak inhibitor and process of preparing the same |
| CN117384163B (zh) * | 2022-07-05 | 2026-02-17 | 盛世泰科生物医药技术(苏州)股份有限公司 | 一种含偕二氟基的化合物及其制备方法和用途 |
| KR20250056924A (ko) | 2022-08-02 | 2025-04-28 | 리미널 바이오사이언시스 리미티드 | 치환된 피리돈 gpr84 길항제 및 이의 용도 |
| US20260028330A1 (en) | 2022-08-02 | 2026-01-29 | Liminal Biosciences Limited | Heteroaryl carboxamide and related gpr84 antagonists and uses thereof |
| IL318577A (en) | 2022-08-02 | 2025-03-01 | Liminal Biosciences Ltd | ARYL-TRIAZOLYL AND RELATED GPR84 ANTAGONISTS AND THEIR USES |
| WO2024028193A1 (en) | 2022-08-03 | 2024-02-08 | Medichem, S.A. | Stable oral pharmaceutical formulation containing ruxolitinib hemifumarate |
| WO2024042448A1 (en) * | 2022-08-22 | 2024-02-29 | Granules India Limited | An improved process for the preparation of ruxolitinib |
| WO2024099396A1 (zh) * | 2022-11-11 | 2024-05-16 | 浙江奥翔药业股份有限公司 | 芦可替尼晶体及其药物组合物 |
| WO2024112894A1 (en) | 2022-11-22 | 2024-05-30 | PIC Therapeutics, Inc. | Eif4e inhibitors and uses thereof |
| WO2024184926A1 (en) * | 2023-03-08 | 2024-09-12 | Aarti Pharmalabs Limited | Process for preparation of chiral ruxolitinib and salts thereof |
| WO2024187415A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| WO2024187416A1 (en) * | 2023-03-15 | 2024-09-19 | Zhejiang Qizheng Pharmaceutical Co., Ltd. | Pharmaceutical composition comprising ruxolitinib |
| WO2024243225A1 (en) | 2023-05-21 | 2024-11-28 | Incyte Corporation | Topical ruxolitinib foam |
| AU2024312190A1 (en) | 2023-06-23 | 2025-07-03 | Kymera Therapeutics, Inc. | Irak degraders and uses thereof |
| EP4491175A1 (en) | 2023-07-10 | 2025-01-15 | Genepharm S.A. | A solid oral composition of ruxolitinib |
| CN121194977A (zh) | 2023-09-04 | 2025-12-23 | 印度颗粒有限公司 | 用于制备芦可替尼及其新晶型的改良方法 |
| IT202300018879A1 (it) | 2023-09-14 | 2025-03-14 | Chemelectiva S R L | Processo enzimatico per la preparazione di (r)-3-(4-bromo-1h-pirazol-1-il)-3- ciclopentilpropanenitrile, quale intermedio nella sintesi di ruxolitinib |
| AU2024344754A1 (en) | 2023-09-21 | 2026-04-02 | Takeda Pharmaceutical Company Limited | Tyk2 inhibitors for use in the treatment of inflammatory bowel disease |
| US12364699B2 (en) | 2023-10-10 | 2025-07-22 | Sun Pharmaceuticals Industries, Inc. | Method of treating hair loss disorders |
| WO2025117642A1 (en) | 2023-12-01 | 2025-06-05 | Incyte Corporation | Ruxolitinib for treating hidradenitis suppurativa (hs) |
| EP4621803A1 (en) | 2024-03-22 | 2025-09-24 | Assistance Publique - Hôpitaux de Paris | Method for identifying patients in need for ici-induced myotoxicity treatment |
| US20260001893A1 (en) * | 2024-03-27 | 2026-01-01 | Gilead Sciences, Inc. | Small molecule modulators of stat6 |
| WO2025226637A1 (en) | 2024-04-22 | 2025-10-30 | Incyte Corporation | Combination therapy with an anti-colony stimulating factor 1 receptor antibody and a jak inhibitor |
| US20260053743A1 (en) | 2024-08-26 | 2026-02-26 | Incyte Corporation | Topical skin formulations of a pharmaceutically acceptable salt of ruxolitinib |
Family Cites Families (311)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US2985589A (en) | 1957-05-22 | 1961-05-23 | Universal Oil Prod Co | Continuous sorption process employing fixed bed of sorbent and moving inlets and outlets |
| US3632836A (en) | 1968-10-25 | 1972-01-04 | Dow Chemical Co | Solid curable polyepoxides modified with hydrolyzed liquid polyepoxides |
| US3832460A (en) | 1971-03-19 | 1974-08-27 | C Kosti | Anesthetic-vasoconstrictor-antihistamine composition for the treatment of hypertrophied oral tissue |
| US4140755A (en) * | 1976-02-13 | 1979-02-20 | Hoffmann-La Roche Inc. | Sustained release tablet formulations |
| DE3036390A1 (de) | 1980-09-26 | 1982-05-13 | Troponwerke GmbH & Co KG, 5000 Köln | Neue pyrrolo-pyrimidine, verfahren zu ihrer herstellung und ihre verwendung bei der herstellung von biologischen wirkstoffen |
| DE3220113A1 (de) | 1982-05-28 | 1983-12-01 | Basf Ag, 6700 Ludwigshafen | Difluormethoxiphenylthiophosphorsaeureester |
| US4402832A (en) | 1982-08-12 | 1983-09-06 | Uop Inc. | High efficiency continuous separation process |
| US4404335A (en) | 1982-08-16 | 1983-09-13 | The Dow Chemical Company | Hydrolyzing epoxy resins in absence of solvent and in presence of oxalic acid and a phosphonium compound |
| US4548990A (en) | 1983-08-15 | 1985-10-22 | Ciba-Geigy Corporation | Crosslinked, porous polymers for controlled drug delivery |
| US4498991A (en) | 1984-06-18 | 1985-02-12 | Uop Inc. | Serial flow continuous separation process |
| NL8403224A (nl) | 1984-10-24 | 1986-05-16 | Oce Andeno Bv | Dioxafosforinanen, de bereiding ervan en de toepassing voor het splitsen van optisch actieve verbindingen. |
| CA1306260C (en) | 1985-10-18 | 1992-08-11 | Shionogi & Co., Ltd. | Condensed imidazopyridine derivatives |
| US4921947A (en) | 1986-03-31 | 1990-05-01 | Eli Lilly And Company | Process for preparing macrolide derivatives |
| JPH0710876Y2 (ja) | 1989-08-31 | 1995-03-15 | 石垣機工株式会社 | スクリュープレスにおける脱水筒の洗浄装置 |
| CA2067221C (en) | 1989-10-11 | 1997-04-15 | Yasuji Sakuma | Fused pyrimidine derivative, process for preparation of same and pharmaceutical preparation comprising same as active ingredient |
| US5403593A (en) | 1991-03-04 | 1995-04-04 | Sandoz Ltd. | Melt granulated compositions for preparing sustained release dosage forms |
| IT1258781B (it) | 1992-01-16 | 1996-02-29 | Zambon Spa | Composizione farmaceutica oftalmica contenente n-acetilcisteina e polivinilalcol |
| US5521184A (en) | 1992-04-03 | 1996-05-28 | Ciba-Geigy Corporation | Pyrimidine derivatives and processes for the preparation thereof |
| FR2695126B1 (fr) | 1992-08-27 | 1994-11-10 | Sanofi Elf | Dérivés d'acide thiényl ou pyrrolyl carboxyliques, leur préparation et médicaments les contenant. |
| AU671491B2 (en) | 1992-12-18 | 1996-08-29 | F. Hoffmann-La Roche Ag | N-oxycarbonyl substituted 5'-deoxy-5-fluorcytidines |
| JPH0710876A (ja) * | 1993-06-24 | 1995-01-13 | Teijin Ltd | ４位に環状アミノ基を有するピロロ［２，３―ｄ］ピリミジン |
| USH1439H (en) | 1993-10-18 | 1995-05-02 | The Dow Chemical Company | Method to increase the level of α-glycol in liquid epoxy resin |
| EP0727217A3 (en) | 1995-02-10 | 1997-01-15 | Suntory Ltd | Pharmaceutical and cosmetic compositions containing God-type ellagitannin as an active ingredient |
| IL117580A0 (en) | 1995-03-29 | 1996-07-23 | Merck & Co Inc | Inhibitors of farnesyl-protein transferase and pharmaceutical compositions containing them |
| US5856326A (en) | 1995-03-29 | 1999-01-05 | Merck & Co., Inc. | Inhibitors of farnesyl-protein transferase |
| JP4010563B2 (ja) | 1995-07-05 | 2007-11-21 | イー・アイ・デユポン・ドウ・ヌムール・アンド・カンパニー | 殺菌・殺カビ性のピリミジノン類 |
| SI9620103A (sl) | 1995-07-06 | 1998-10-31 | Novartis Ag | Pirolopirimidini in postopki za njihovo pripravo |
| US5630943A (en) | 1995-11-30 | 1997-05-20 | Merck Patent Gesellschaft Mit Beschrankter Haftung | Discontinuous countercurrent chromatographic process and apparatus |
| GB9604361D0 (en) | 1996-02-29 | 1996-05-01 | Pharmacia Spa | 4-Substituted pyrrolopyrimidine compounds as tyrosine kinase inhibitors |
| CA2250232A1 (en) | 1996-04-03 | 1997-10-09 | Allen I. Oliff | A method of treating cancer |
| CA2251955A1 (en) | 1996-04-18 | 1997-10-23 | Nancy E. Kohl | A method of treating cancer |
| US5795909A (en) | 1996-05-22 | 1998-08-18 | Neuromedica, Inc. | DHA-pharmaceutical agent conjugates of taxanes |
| EP0934270A1 (en) | 1996-05-30 | 1999-08-11 | Merck & Co., Inc. | A method of treating cancer |
| US6624138B1 (en) | 2001-09-27 | 2003-09-23 | Gp Medical | Drug-loaded biological material chemically treated with genipin |
| AU724216B2 (en) | 1997-04-07 | 2000-09-14 | Merck & Co., Inc. | A method of treating cancer |
| US6060038A (en) | 1997-05-15 | 2000-05-09 | Merck & Co., Inc. | Radiolabeled farnesyl-protein transferase inhibitors |
| US6063284A (en) | 1997-05-15 | 2000-05-16 | Em Industries, Inc. | Single column closed-loop recycling with periodic intra-profile injection |
| CA2295620A1 (en) | 1997-08-11 | 1999-02-18 | Boehringer Ingelheim Pharmaceuticals, Inc. | 5,6-heteroaryl-dipyrido¬2,3-b:3',2'-f|azepines and their use in the prevention or treatment of hiv infection |
| US7153845B2 (en) | 1998-08-25 | 2006-12-26 | Columbia Laboratories, Inc. | Bioadhesive progressive hydration tablets |
| US6075056A (en) | 1997-10-03 | 2000-06-13 | Penederm, Inc. | Antifungal/steroid topical compositions |
| SE9800729L (sv) | 1998-03-06 | 1999-09-07 | Scotia Lipidteknik Ab | Ny topikal formulering I |
| US6025366A (en) | 1998-04-02 | 2000-02-15 | Merck & Co., Inc. | Antagonists of gonadotropin releasing hormone |
| US6232320B1 (en) | 1998-06-04 | 2001-05-15 | Abbott Laboratories | Cell adhesion-inhibiting antiinflammatory compounds |
| AU4231299A (en) | 1998-06-04 | 1999-12-20 | Abbott Laboratories | Cell adhesion-inhibiting antinflammatory compounds |
| PA8474101A1 (es) * | 1998-06-19 | 2000-09-29 | Pfizer Prod Inc | Compuestos de pirrolo [2,3-d] pirimidina |
| SK286640B6 (sk) | 1998-06-19 | 2009-03-05 | Pfizer Products Inc. | Pyrol [2,3-d] pyrimidínová zlúčenina, jej použitie na výrobu liečiva, farmaceutická kompozícia s jej obsahom, použitie jej kombinácie s ďalšími činidlami a súpravy s jej obsahom na výrobu liečiva |
| PT1107964E (pt) | 1998-08-11 | 2010-06-11 | Novartis Ag | Derivados de isoquinolina com actividade inibidora da angiogénese |
| JP2000119271A (ja) | 1998-08-12 | 2000-04-25 | Hokuriku Seiyaku Co Ltd | １ｈ―イミダゾピリジン誘導体 |
| DE69905380T2 (de) | 1998-09-10 | 2003-11-27 | Nycomed Danmark A/S, Roskilde | Pharmazeutische zusammensetzungen mit schneller freisetzung von wirkstoffen |
| US6413419B1 (en) | 1998-10-29 | 2002-07-02 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic |
| US6375839B1 (en) | 1998-10-29 | 2002-04-23 | Institut Francais Du Petrole | Process and device for separation with variable-length chromatographic zones |
| FR2785196B1 (fr) | 1998-10-29 | 2000-12-15 | Inst Francais Du Petrole | Procede et dispositif de separation avec des zones chromatographiques a longueur variable |
| US6133031A (en) | 1999-08-19 | 2000-10-17 | Isis Pharmaceuticals Inc. | Antisense inhibition of focal adhesion kinase expression |
| AU3248600A (en) | 1999-03-03 | 2000-09-21 | Merck & Co., Inc. | Inhibitors of prenyl-protein transferases |
| GB9905075D0 (en) | 1999-03-06 | 1999-04-28 | Zeneca Ltd | Chemical compounds |
| US6217895B1 (en) | 1999-03-22 | 2001-04-17 | Control Delivery Systems | Method for treating and/or preventing retinal diseases with sustained release corticosteroids |
| US6239113B1 (en) | 1999-03-31 | 2001-05-29 | Insite Vision, Incorporated | Topical treatment or prevention of ocular infections |
| AU3565999A (en) | 1999-04-16 | 2000-11-02 | Coelacanth Chemical Corporation | Synthesis of azetidine derivatives |
| US6921763B2 (en) | 1999-09-17 | 2005-07-26 | Abbott Laboratories | Pyrazolopyrimidines as therapeutic agents |
| US6699880B1 (en) | 1999-10-13 | 2004-03-02 | Banyu Pharmaceutical Co., Ltd. | Substituted imidazolidinone derivatives |
| US7235258B1 (en) | 1999-10-19 | 2007-06-26 | Nps Pharmaceuticals, Inc. | Sustained-release formulations for treating CNS-mediated disorders |
| DE60037345T2 (de) * | 1999-12-10 | 2008-11-13 | Pfizer Products Inc., Groton | Pyrrolo(2,3-d)pyrimidin-Verbindungen |
| WO2001047922A2 (en) * | 1999-12-24 | 2001-07-05 | Aventis Pharma Limited | Azaindoles |
| GB0004890D0 (en) | 2000-03-01 | 2000-04-19 | Astrazeneca Uk Ltd | Chemical compounds |
| US7235551B2 (en) | 2000-03-02 | 2007-06-26 | Smithkline Beecham Corporation | 1,5-disubstituted-3,4-dihydro-1h-pyrimido[4,5-d]pyrimidin-2-one compounds and their use in treating csbp/p38 kinase mediated diseases |
| EP1142566B1 (fr) | 2000-04-07 | 2003-10-01 | Laboratoire Medidom S.A. | Formulations ophtalmiques à base de ciclosporine, d'acide hyaluronique et du polysorbate |
| WO2001081345A1 (en) | 2000-04-20 | 2001-11-01 | Mitsubishi Pharma Corporation | Aromatic amide compounds |
| GEP20084317B (en) * | 2000-04-25 | 2008-02-25 | Icos Corp | Inhibitors of human phosphatidyl-inositol 3-kinase delta |
| US7498304B2 (en) | 2000-06-16 | 2009-03-03 | Curis, Inc. | Angiogenesis-modulating compositions and uses |
| AU7549501A (en) | 2000-06-16 | 2002-01-02 | Biogen Inc | Angiogenesis-modulating compositions and uses |
| US6335342B1 (en) | 2000-06-19 | 2002-01-01 | Pharmacia & Upjohn S.P.A. | Azaindole derivatives, process for their preparation, and their use as antitumor agents |
| CN100548375C (zh) | 2000-06-23 | 2009-10-14 | 田边三菱制药株式会社 | 抗肿瘤作用增效剂 |
| ATE423120T1 (de) * | 2000-06-26 | 2009-03-15 | Pfizer Prod Inc | Pyrroloä2,3-düpyrimidin verbindungen als immunosuppressive wirkstoffe |
| KR100786927B1 (ko) | 2000-06-28 | 2007-12-17 | 스미스클라인비이참피이엘시이 | 습식 분쇄방법 |
| AU2001278790A1 (en) | 2000-08-22 | 2002-03-04 | Hokuriku Seiyaku Co. Ltd | 1h-imidazopyridine derivatives |
| ATE407132T1 (de) | 2000-12-05 | 2008-09-15 | Vertex Pharma | Inhibitoren von c-jun n-terminalen kinasen (jnk) und anderen proteinkinasen |
| GB0100622D0 (en) | 2001-01-10 | 2001-02-21 | Vernalis Res Ltd | Chemical compounds V111 |
| JP2004520347A (ja) | 2001-01-15 | 2004-07-08 | グラクソ グループ リミテッド | Ｌｄｌ−受容体発現のインデューサーとしてのアリールピペリジンおよびピペラジン誘導体 |
| US20040102455A1 (en) | 2001-01-30 | 2004-05-27 | Burns Christopher John | Method of inhibiting kinases |
| WO2002092573A2 (en) | 2001-05-16 | 2002-11-21 | Vertex Pharmaceuticals Incorporated | Heterocyclic substituted pyrazoles as inhibitors of src and other protein kinases |
| US7301023B2 (en) | 2001-05-31 | 2007-11-27 | Pfizer Inc. | Chiral salt resolution |
| GB0115109D0 (en) * | 2001-06-21 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| GB0115393D0 (en) | 2001-06-23 | 2001-08-15 | Aventis Pharma Ltd | Chemical compounds |
| EP1414443B1 (en) | 2001-08-01 | 2006-11-15 | Merck & Co., Inc. | BENZIMIDAZO 4,5-f|ISOQUINOLINONE DERIVATIVES |
| BR0212760A (pt) | 2001-09-19 | 2004-12-07 | Aventis Pharma Sa | Compostos quìmicos |
| US6429231B1 (en) | 2001-09-24 | 2002-08-06 | Bradley Pharmaceuticals, Inc. | Compositions containing antimicrobials and urea for the treatment of dermatological disorders and methods for their use |
| DE60213842T2 (de) | 2001-10-30 | 2007-09-06 | Novartis Ag | Staurosporin-derivate als hemmer der flt3-rezeptor-tyrosinkinase-wirkung |
| JP2003155285A (ja) | 2001-11-19 | 2003-05-27 | Toray Ind Inc | 環状含窒素誘導体 |
| KR20040058340A (ko) | 2001-11-30 | 2004-07-03 | 데이진 가부시키가이샤 | 5-(3-시아노페닐)-3-포르밀벤조산 화합물의 제조 방법 |
| PY0228255A (es) | 2001-12-06 | 2004-06-01 | Pfizer Prod Inc | Compuestos cristalinos novedosos |
| US6995144B2 (en) | 2002-03-14 | 2006-02-07 | Eisai Co., Ltd. | Nitrogen containing heterocyclic compounds and medicines containing the same |
| EA007156B1 (ru) | 2002-04-15 | 2006-08-25 | Адамс Лэборетриз, Инк. | Замедленно высвобождающие лекарственные композиции гвайфенезина |
| TW200403058A (en) | 2002-04-19 | 2004-03-01 | Bristol Myers Squibb Co | Heterocyclo inhibitors of potassium channel function |
| US7304061B2 (en) | 2002-04-26 | 2007-12-04 | Vertex Pharmaceuticals Incorporated | Heterocyclic inhibitors of ERK2 and uses thereof |
| ATE381332T1 (de) | 2002-05-02 | 2008-01-15 | Merck & Co Inc | Tyrosinkinase-hemmer |
| BR0309844A (pt) | 2002-05-07 | 2005-02-15 | Control Delivery Sys Inc | Processos para formação de um dispositivo para a distribuição de droga |
| CA2486183C (en) | 2002-05-23 | 2012-01-10 | Cytopia Pty Ltd. | Protein kinase inhibitors |
| PE20040522A1 (es) | 2002-05-29 | 2004-09-28 | Novartis Ag | Derivados de diarilurea dependientes de la cinasa de proteina |
| CA2490340A1 (en) * | 2002-06-26 | 2004-01-08 | Idemitsu Kosan Co., Ltd. | Hydrogenated copolymer, production process for the same and hot melt adhesive composition using the same |
| GB0215676D0 (en) | 2002-07-05 | 2002-08-14 | Novartis Ag | Organic compounds |
| GB0215844D0 (en) | 2002-07-09 | 2002-08-14 | Novartis Ag | Organic compounds |
| AU2003252478A1 (en) | 2002-07-10 | 2004-02-02 | Ono Pharmaceutical Co., Ltd. | Ccr4 antagonist and medicinal use thereof |
| EP1542768A1 (en) | 2002-09-20 | 2005-06-22 | Alcon, Inc. | Use of cytokine synthesis inhibitors for the treatment of dry eye disorders |
| US20040204404A1 (en) | 2002-09-30 | 2004-10-14 | Robert Zelle | Human N-type calcium channel blockers |
| US7259161B2 (en) | 2002-11-04 | 2007-08-21 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of JAK and other protein kinases |
| US8034831B2 (en) | 2002-11-06 | 2011-10-11 | Celgene Corporation | Methods for the treatment and management of myeloproliferative diseases using 4-(amino)-2-(2,6-Dioxo(3-piperidyl)-isoindoline-1,3-dione in combination with other therapies |
| TWI335913B (en) | 2002-11-15 | 2011-01-11 | Vertex Pharma | Diaminotriazoles useful as inhibitors of protein kinases |
| US20040099204A1 (en) | 2002-11-25 | 2004-05-27 | Nestor John J. | Sheet, page, line, position marker |
| NZ539901A (en) | 2002-11-26 | 2007-09-28 | Pfizer Prod Inc | Method of treatment of transplant rejection |
| UA80767C2 (en) | 2002-12-20 | 2007-10-25 | Pfizer Prod Inc | Pyrimidine derivatives for the treatment of abnormal cell growth |
| TWI335819B (en) | 2002-12-24 | 2011-01-11 | Alcon Inc | Use of oculosurface selective glucocorticoid in the treatment of dry eye |
| US7135493B2 (en) | 2003-01-13 | 2006-11-14 | Astellas Pharma Inc. | HDAC inhibitor |
| US7444183B2 (en) | 2003-02-03 | 2008-10-28 | Enteromedics, Inc. | Intraluminal electrode apparatus and method |
| JP2006518381A (ja) | 2003-02-07 | 2006-08-10 | バーテックス ファーマシューティカルズ インコーポレイテッド | プロテインキナーゼのインヒビターとして有用なヘテロアリール置換ピロール |
| GB0305929D0 (en) | 2003-03-14 | 2003-04-23 | Novartis Ag | Organic compounds |
| AU2004230841A1 (en) | 2003-04-03 | 2004-10-28 | Vertex Pharmaceuticals Incorporated | Compositions useful as inhibitors of protein kinases |
| SE0301373D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| SE0301372D0 (sv) * | 2003-05-09 | 2003-05-09 | Astrazeneca Ab | Novel compounds |
| FR2857454B1 (fr) | 2003-07-08 | 2006-08-11 | Aventis Pasteur | Dosage des acides techoiques des bacteries gram+ |
| US20050043346A1 (en) * | 2003-08-08 | 2005-02-24 | Pharmacia Italia S.P.A. | Pyridylpyrrole derivatives active as kinase inhibitors |
| EP1663204B1 (en) | 2003-08-29 | 2014-05-07 | Exelixis, Inc. | C-kit modulators and methods of use |
| US8084457B2 (en) | 2003-09-15 | 2011-12-27 | Lead Discovery Center Gmbh | Pharmaceutically active 4,6-disubstituted aminopyrimidine derivatives as modulators of protein kinases |
| AR045944A1 (es) | 2003-09-24 | 2005-11-16 | Novartis Ag | Derivados de isoquinolina 1.4-disustituidas |
| US7358255B2 (en) | 2003-10-24 | 2008-04-15 | Santen Pharmaceutical Co., Ltd. | Therapeutic agent for keratoconjunctival disorder |
| US7387793B2 (en) | 2003-11-14 | 2008-06-17 | Eurand, Inc. | Modified release dosage forms of skeletal muscle relaxants |
| MY141220A (en) | 2003-11-17 | 2010-03-31 | Astrazeneca Ab | Pyrazole derivatives as inhibitors of receptor tyrosine kinases |
| EP1689407A1 (en) | 2003-11-25 | 2006-08-16 | Pfizer Products Inc. | Method of treatment of atherosclerosis |
| SG133602A1 (en) | 2003-12-17 | 2007-07-30 | Pfizer Prod Inc | Pyrrolo [2,3-d] pyrimidine compounds for treating transplant rejection |
| CN1925855B (zh) | 2003-12-19 | 2010-06-16 | 普莱希科公司 | 开发Ret调节剂的化合物和方法 |
| ES2308299T3 (es) | 2003-12-19 | 2008-12-01 | Schering Corp | Tiadiazoles como ligandos de receptores de cxc-y cc-quimioquinas. |
| MXPA06007326A (es) | 2003-12-23 | 2007-01-26 | Astex Therapeutics Ltd | Derivados de pirazol como moduladores de proteina cinasa. |
| US20050239806A1 (en) * | 2004-01-13 | 2005-10-27 | Ambit Biosciences Corporation | Pyrrolopyrimidine derivatives and analogs and their use in the treatment and prevention of diseases |
| CA2559285A1 (en) | 2004-03-18 | 2005-09-29 | Brigham And Women's Hospital, Inc. | Methods for the treatment of synucleinopathies |
| ES2364340T3 (es) | 2004-03-30 | 2011-08-31 | Vertex Pharmaceuticals Incorporated | Azaindoles útiles como inhibidores de jak y otras proteína quinasas. |
| WO2005117909A2 (en) | 2004-04-23 | 2005-12-15 | Exelixis, Inc. | Kinase modulators and methods of use |
| US20060106020A1 (en) | 2004-04-28 | 2006-05-18 | Rodgers James D | Tetracyclic inhibitors of Janus kinases |
| WO2005105988A2 (en) | 2004-04-28 | 2005-11-10 | Vertex Pharmaceuticals Incorporated | Crystal structure of human jak3 kinase domain complex and binding pockets thereof |
| AU2005237254B2 (en) | 2004-05-03 | 2010-02-04 | Novartis Ag | Combinations comprising a S1P receptor agonist and a JAK3 kinase inhibitor |
| WO2005110410A2 (en) | 2004-05-14 | 2005-11-24 | Abbott Laboratories | Kinase inhibitors as therapeutic agents |
| PE20060426A1 (es) | 2004-06-02 | 2006-06-28 | Schering Corp | DERIVADOS DE ACIDO TARTARICO COMO INHIBIDORES DE MMPs, ADAMs, TACE Y TNF-alfa |
| RU2401265C2 (ru) | 2004-06-10 | 2010-10-10 | Айрм Ллк | Соединения и композиции в качестве ингибиторов протеинкиназы |
| JP5315611B2 (ja) | 2004-06-23 | 2013-10-16 | 小野薬品工業株式会社 | Ｓ１ｐ受容体結合能を有する化合物およびその用途 |
| CA2572058A1 (en) | 2004-06-30 | 2006-01-12 | Vertex Pharmaceuticals Incorporated | Azaindoles useful as inhibitors of protein kinases |
| US7138423B2 (en) | 2004-07-20 | 2006-11-21 | Bristol-Myers Squibb Company | Arylpyrrolidine derivatives as NK-1 /SSRI antagonists |
| FR2873691B1 (fr) | 2004-07-29 | 2006-10-06 | Sanofi Synthelabo | Derives d'amino-piperidine, leur preparation et leur application en therapeutique |
| WO2006013114A1 (en) | 2004-08-06 | 2006-02-09 | Develogen Aktiengesellschaft | Use of a timp-2 secreted protein product for preventing and treating pancreatic diseases and/or obesity and/or metabolic syndrome |
| WO2006022459A1 (en) | 2004-08-23 | 2006-03-02 | Mogam Biotechnology Institute | Primer and probe for detection of sars coronavirus, kit comprising the primer and/or the probe, and detection method thereof |
| GB0421525D0 (en) | 2004-09-28 | 2004-10-27 | Novartis Ag | Inhibitors of protein kineses |
| US20070054916A1 (en) | 2004-10-01 | 2007-03-08 | Amgen Inc. | Aryl nitrogen-containing bicyclic compounds and methods of use |
| KR100858262B1 (ko) | 2004-10-13 | 2008-09-11 | 에프. 호프만-라 로슈 아게 | Ｃｄｋ2 및 혈관신생에 대한 저해제로서 유용하고, 유방암,대장암, 폐암 및 전립선암의 치료용으로 유용한이중치환된 피라졸로벤조디아제핀 |
| MY179032A (en) | 2004-10-25 | 2020-10-26 | Cancer Research Tech Ltd | Ortho-condensed pyridine and pyrimidine derivatives (e.g.purines) as protein kinase inhibitors |
| UY29177A1 (es) | 2004-10-25 | 2006-05-31 | Astex Therapeutics Ltd | Derivados sustituidos de purina, purinona y deazapurina, composiciones que los contienen métodos para su preparación y sus usos |
| PT1812440E (pt) | 2004-11-04 | 2011-01-25 | Vertex Pharma | Pirazolo[1,5-a]pirimidinas úteis enquanto inibidores de proteínas cinases |
| AU2005309019A1 (en) | 2004-11-24 | 2006-06-01 | Novartis Ag | Combinations of JAK inhibitors and at least one of Bcr-Abl, Flt-3, FAK or RAF kinase inhibitors |
| US7517870B2 (en) | 2004-12-03 | 2009-04-14 | Fondazione Telethon | Use of compounds that interfere with the hedgehog signaling pathway for the manufacture of a medicament for preventing, inhibiting, and/or reversing ocular diseases related with ocular neovascularization |
| US20060128803A1 (en) | 2004-12-14 | 2006-06-15 | Alcon, Inc. | Method of treating dry eye disorders using 13(S)-HODE and its analogs |
| WO2006067445A2 (en) | 2004-12-22 | 2006-06-29 | Astrazeneca Ab | Csf-1r kinase inhibitors |
| AR054416A1 (es) | 2004-12-22 | 2007-06-27 | Incyte Corp | Pirrolo [2,3-b]piridin-4-il-aminas y pirrolo [2,3-b]pirimidin-4-il-aminas como inhibidores de las quinasas janus. composiciones farmaceuticas. |
| CA2595574A1 (en) | 2005-01-20 | 2006-07-27 | Pfizer Limited. | Chemical compounds |
| KR20070104641A (ko) | 2005-02-03 | 2007-10-26 | 버텍스 파마슈티칼스 인코포레이티드 | 단백질 키나제의 억제제로 유용한 피롤로피리미딘 |
| US7683171B2 (en) | 2005-02-04 | 2010-03-23 | Bristol-Myers Squibb Company | 1H-imidazo[4,5-d]thieno[3,2-b]pyridine based tricyclic compounds and pharmaceutical compositions comprising same |
| US20080188483A1 (en) | 2005-03-15 | 2008-08-07 | Irm Llc | Compounds and Compositions as Protein Kinase Inhibitors |
| JP2008534689A (ja) | 2005-04-05 | 2008-08-28 | ファーマコペイア， インコーポレイテッド | 免疫抑制のためのプリン及びイミダゾピリジン誘導体 |
| GB0510139D0 (en) | 2005-05-18 | 2005-06-22 | Addex Pharmaceuticals Sa | Novel compounds B1 |
| GB0510390D0 (en) | 2005-05-20 | 2005-06-29 | Novartis Ag | Organic compounds |
| EP2354140A1 (en) | 2005-05-20 | 2011-08-10 | Vertex Pharmaceuticals Incorporated | Pyrrolopyridines useful as inhibitors of protein kinase |
| BRPI0610876B8 (pt) | 2005-06-08 | 2021-05-25 | Rigel Pharmaceuticals Inc | composto, formulação farmacêutica, e métodos de inibir uma atividade de uma jak cinase, e de inibir uma cascata de transdução de sinal em que jak3 cinase desempenha um papel |
| WO2006136823A1 (en) | 2005-06-21 | 2006-12-28 | Astex Therapeutics Limited | Heterocyclic containing amines as kinase b inhibitors |
| UA95244C2 (ru) | 2005-06-22 | 2011-07-25 | Плексикон, Инк. | Соединения и способ модулирования активности киназ, и показания для их применения |
| CN102127078A (zh) | 2005-07-14 | 2011-07-20 | 安斯泰来制药株式会社 | Janus激酶3的杂环类抑制剂 |
| FR2889662B1 (fr) | 2005-08-11 | 2011-01-14 | Galderma Res & Dev | Emulsion de type huile-dans-eau pour application topique en dermatologie |
| US20070049591A1 (en) | 2005-08-25 | 2007-03-01 | Kalypsys, Inc. | Inhibitors of MAPK/Erk Kinase |
| CA2621261C (en) | 2005-09-22 | 2014-05-20 | Incyte Corporation | Azepine inhibitors of janus kinases |
| ZA200802685B (en) | 2005-09-30 | 2009-10-28 | Vertex Pharma | Deazapurines useful as inhibitors of janus kinases |
| WO2007044894A2 (en) | 2005-10-11 | 2007-04-19 | Chembridge Research Laboratories, Inc. | Cell-free protein expression systems and methods of use thereof |
| PL1937664T3 (pl) | 2005-10-14 | 2011-11-30 | Sumitomo Chemical Co | Związki hydrazydowe i ich zastosowanie jako pestycydy |
| JP2009513615A (ja) | 2005-10-28 | 2009-04-02 | アストラゼネカ アクチボラグ | 癌の治療においてチロシンキナーゼ阻害剤として使用するための４−（３−アミノピラゾール）ピリミジン誘導体 |
| JP5191391B2 (ja) | 2005-11-01 | 2013-05-08 | ターゲジェン インコーポレーティッド | キナーゼのビ−アリールメタ−ピリミジン阻害剤 |
| WO2007062459A1 (en) | 2005-11-29 | 2007-06-07 | Cytopia Research Pty Ltd | Selective kinase inhibitors based on pyridine scaffold |
| US20130137681A1 (en) | 2005-12-13 | 2013-05-30 | Incyte Corporation | HETEROARYL SUBSTITUTED PYRROLO[2,3-b]PYRIDINES AND PYRROLO[2,3-b]PYRIMIDINES AS JANUS KINASE INHIBITORS |
| SG10202003901UA (en) * | 2005-12-13 | 2020-05-28 | Incyte Holdings Corp | Heteroaryl substituted pyrrolo[2,3-b]pyridines and pyrrolo[2,3-b]pyrimidines as janus kinase inhibitors |
| WO2007076423A2 (en) | 2005-12-22 | 2007-07-05 | Smithkline Beecham Corporation | INHIBITORS OF Akt ACTIVITY |
| EA200870117A1 (ru) | 2005-12-23 | 2008-12-30 | Смитклайн Бичам Корпорейшн | Азаиндоловые ингибиторы аурора-киназ |
| JP4643455B2 (ja) | 2006-01-12 | 2011-03-02 | 株式会社ユニバーサルエンターテインメント | 遊技システム |
| UA95940C2 (uk) | 2006-01-17 | 2011-09-26 | Вертекс Фармасьютикалс Інкорпорейтед | Азаіндоли як інгібітори кіназ януса |
| WO2007084667A2 (en) | 2006-01-19 | 2007-07-26 | Osi Pharmaceutical, Inc. | Fused heterobicyclic kinase inhibitors |
| EP1981887A2 (en) | 2006-02-01 | 2008-10-22 | SmithKline Beecham Corporation | Pyrrolo[2,3,b]pyridine derivatives useful as raf kinase inhibitors |
| US7745477B2 (en) | 2006-02-07 | 2010-06-29 | Hoffman-La Roche Inc. | Heteroaryl and benzyl amide compounds |
| US20070202172A1 (en) | 2006-02-24 | 2007-08-30 | Tomer Gold | Metoprolol succinate E.R. tablets and methods for their preparation |
| CA2644368A1 (en) | 2006-03-10 | 2007-09-20 | Ono Pharmaceutical Co., Ltd. | Nitrogenated heterocyclic derivative, and pharmaceutical agent comprising the derivative as active ingredient |
| PL2003132T3 (pl) | 2006-04-03 | 2014-10-31 | Astellas Pharma Inc | Pochodne oksadiazolu jako agoniści S1P1 |
| SG170828A1 (en) | 2006-04-05 | 2011-05-30 | Vertex Pharmaceuticals Inc Us | Deazapurines useful as inhibitors of janus kinases |
| EP2059515A2 (en) | 2006-04-12 | 2009-05-20 | Pfizer Limited | Pyrrolidine derivatives as modulators of chemokine ccr5 receptors |
| WO2007129195A2 (en) | 2006-05-04 | 2007-11-15 | Pfizer Products Inc. | 4-pyrimidine-5-amino-pyrazole compounds |
| US20080051427A1 (en) | 2006-05-18 | 2008-02-28 | Fritz Schuckler | Pharmaceutical Compositions and Methods of Using Same |
| US7691811B2 (en) | 2006-05-25 | 2010-04-06 | Bodor Nicholas S | Transporter-enhanced corticosteroid activity and methods and compositions for treating dry eye |
| TWI398252B (zh) | 2006-05-26 | 2013-06-11 | 諾華公司 | 吡咯并嘧啶化合物及其用途 |
| NZ573174A (en) | 2006-06-01 | 2012-01-12 | Msd Consumer Care Inc | Sustained release pharmaceutical dosage form containing phenylephrine |
| AU2007275221A1 (en) | 2006-07-20 | 2008-01-24 | Allen J. Borchardt | Benzothiophene inhibitors of RHO kinase |
| WO2008013622A2 (en) | 2006-07-27 | 2008-01-31 | E. I. Du Pont De Nemours And Company | Fungicidal azocyclic amides |
| US8492378B2 (en) | 2006-08-03 | 2013-07-23 | Takeda Pharmaceutical Company Limited | GSK-3β inhibitor |
| CA2660560A1 (en) | 2006-08-16 | 2008-02-21 | Boehringer Ingelheim International Gmbh | Pyrazine compounds, their use and methods of preparation |
| KR20090060333A (ko) | 2006-09-08 | 2009-06-11 | 노파르티스 아게 | 림프구 상호작용에 의해 매개되는 질환의 치료에 유용한 ｎ-바이아릴 (헤테로)아릴술폰아미드 유도체 |
| WO2008035376A2 (en) | 2006-09-19 | 2008-03-27 | Council Of Scientific & Industrial Research | A novel bio-erodible insert for ophthalmic applications and a process for the preparation thereof |
| US7919490B2 (en) | 2006-10-04 | 2011-04-05 | Wyeth Llc | 6-substituted 2-(benzimidazolyl)purine and purinone derivatives for immunosuppression |
| TW200837064A (en) | 2006-10-04 | 2008-09-16 | Pharmacopeia Inc | 8-substituted 2-(benzimidazolyl)purine derivatives for immunosuppression |
| US20120225057A1 (en) | 2006-10-11 | 2012-09-06 | Deciphera Pharmaceuticals, Llc | Methods and compositions for the treatment of myeloproliferative diseases and other proliferative diseases |
| WO2008058126A2 (en) | 2006-11-06 | 2008-05-15 | Supergen, Inc. | Imidazo[1,2-b]pyridazine and pyrazolo[1,5-a]pyrimidine derivatives and their use as protein kinase inhibitors |
| US20080119496A1 (en) | 2006-11-16 | 2008-05-22 | Pharmacopeia Drug Discovery, Inc. | 7-Substituted Purine Derivatives for Immunosuppression |
| RS54510B1 (sr) | 2006-11-22 | 2016-06-30 | Incyte Holdings Corporation | Imidazotriazini i imidazopirimidini kao inhibitori kinaze |
| WO2008067119A2 (en) | 2006-11-27 | 2008-06-05 | Smithkline Beecham Corporation | Novel compounds |
| EP2109364A4 (en) | 2006-12-15 | 2010-04-14 | Abbott Lab | NOVEL OXADIAZONE COMPOUNDS |
| AU2007338792B2 (en) | 2006-12-20 | 2012-05-31 | Amgen Inc. | Substituted heterocycles and methods of use |
| EP2118088B1 (en) | 2006-12-20 | 2012-05-30 | Amgen Inc. | Heterocyclic compounds and their use in treating inflammation, angiogenesis and cancer |
| US8389014B2 (en) | 2006-12-22 | 2013-03-05 | Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. | Gel useful for the delivery of ophthalmic drugs |
| CA2673038C (en) | 2006-12-22 | 2015-12-15 | Incyte Corporation | Substituted tricyclic heteroaryl compounds as janus kinase inhibitors |
| WO2008082839A2 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| KR20080062876A (ko) | 2006-12-29 | 2008-07-03 | 주식회사 대웅제약 | 신규한 항진균성 트리아졸 유도체 |
| WO2008082840A1 (en) | 2006-12-29 | 2008-07-10 | Abbott Laboratories | Pim kinase inhibitors as cancer chemotherapeutics |
| CA2679659C (en) | 2007-03-01 | 2016-01-19 | Novartis Ag | Pim kinase inhibitors and methods of their use |
| NZ580327A (en) | 2007-04-03 | 2012-02-24 | Array Biopharma Inc | IMIDAZO[1,2-a]PYRIDINE COMPOUNDS AS RECEPTOR TYROSINE KINASE INHIBITORS |
| US8188178B2 (en) | 2007-05-07 | 2012-05-29 | 3M Innovative Properties Company | Cold shrinkable article including an epichlorohydrin composition |
| GB0709031D0 (en) | 2007-05-10 | 2007-06-20 | Sareum Ltd | Pharmaceutical compounds |
| JP5603770B2 (ja) | 2007-05-31 | 2014-10-08 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｃｃｒ２受容体拮抗薬およびその使用 |
| GB0710528D0 (en) | 2007-06-01 | 2007-07-11 | Glaxo Group Ltd | Novel compounds |
| KR20150036210A (ko) | 2007-06-13 | 2015-04-07 | 인사이트 코포레이션 | 야누스 키나제 억제제（Ｒ）―３―（４―（７Ｈ―피롤로［２，３－ｄ］피리미딘―4―일）―1Ｈ―피라졸―1―일）―３―사이클로펜틸프로판니트릴의 염 |
| CL2008001709A1 (es) | 2007-06-13 | 2008-11-03 | Incyte Corp | Compuestos derivados de pirrolo [2,3-b]pirimidina, moduladores de quinasas jak; composicion farmaceutica; y uso en el tratamiento de enfermedades tales como cancer, psoriasis, artritis reumatoide, entre otras. |
| NZ582188A (en) | 2007-07-11 | 2012-03-30 | Pfizer | Pharmaceutical compositions and methods of treating dry eye disorders |
| WO2009016460A2 (en) | 2007-08-01 | 2009-02-05 | Pfizer Inc. | Pyrazole compounds and their use as raf inhibitors |
| WO2009049028A1 (en) | 2007-10-09 | 2009-04-16 | Targegen Inc. | Pyrrolopyrimidine compounds and their use as janus kinase modulators |
| EP2217235A4 (en) | 2007-11-15 | 2011-01-12 | Musc Found For Res Dev | INHIBITORS OF PIM PROTEIN KINASES, COMPOSITIONS AND METHOD FOR THE TREATMENT OF CANCER |
| UA104849C2 (uk) | 2007-11-16 | 2014-03-25 | Інсайт Корпорейшн | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus |
| GB0723815D0 (en) | 2007-12-05 | 2008-01-16 | Glaxo Group Ltd | Compounds |
| PT2231689T (pt) | 2008-01-18 | 2016-10-07 | Inst Of Organic Chemistry And Biochemistry Of The Acad Of Sciences Of The Czech Republic | Novos nucleósidos 7-deazapurina citostáticos |
| CA2714181C (en) | 2008-02-04 | 2013-12-24 | Mercury Therapeutics, Inc. | Ampk modulators |
| PE20091577A1 (es) | 2008-03-03 | 2009-11-05 | Novartis Ag | Inhibidores de cinasa pim y metodos para su uso |
| HUE029767T2 (en) | 2008-03-11 | 2017-04-28 | Incyte Holdings Corp | JAK inhibitor azetidine and cyclobutane derivatives |
| WO2009115572A2 (en) | 2008-03-21 | 2009-09-24 | Novartis Ag | Novel heterocyclic compounds and uses therof |
| EP2299816B1 (en) | 2008-06-18 | 2013-11-13 | Merck Sharp & Dohme Corp. | Inhibitors of janus kinases |
| KR101848095B1 (ko) | 2008-06-26 | 2018-04-11 | 안테리오스, 인코퍼레이티드 | 경피 운반 |
| UY31952A (es) | 2008-07-02 | 2010-01-29 | Astrazeneca Ab | 5-metilideno-1,3-tiazolidina-2,4-dionas sustituidas como inhibidores de quinasa pim |
| FR2933409B1 (fr) | 2008-07-03 | 2010-08-27 | Centre Nat Rech Scient | NOUVEAUX PYRROLO °2,3-a! CARBAZOLES ET LEUR UTILISATION COMME INHIBITEURS DES KINASES PIM |
| US8557809B2 (en) | 2008-08-19 | 2013-10-15 | Array Biopharma Inc. | Triazolopyridine compounds as PIM kinase inhibitors |
| TWI496779B (zh) | 2008-08-19 | 2015-08-21 | Array Biopharma Inc | 作為ｐｉｍ激酶抑制劑之三唑吡啶化合物 |
| KR101335843B1 (ko) | 2008-08-20 | 2013-12-02 | 조에티스 엘엘씨 | 피롤로[2,3-ｄ]피리미딘 화합물 |
| BRPI0918846A2 (pt) | 2008-09-02 | 2019-09-24 | Novartis Ag | inibidores de cinase heterocíclica |
| PL2344474T3 (pl) | 2008-09-02 | 2016-03-31 | Novartis Ag | Pochodne pikolinamidu jako inhibitory kinaz |
| JP5564045B2 (ja) | 2008-09-02 | 2014-07-30 | ノバルティス アーゲー | 二環式キナーゼ阻害剤 |
| CL2009001884A1 (es) | 2008-10-02 | 2010-05-14 | Incyte Holdings Corp | Uso de 3-ciclopentil-3-[4-(7h-pirrolo[2,3-d]pirimidin-4-il)-1h-pirazol-1-il)propanonitrilo, inhibidor de janus quinasa, y uso de una composición que lo comprende para el tratamiento del ojo seco. |
| US20110183958A1 (en) | 2008-10-17 | 2011-07-28 | Merck Frosst Canada Ltd. | Azetidine derivatives as inhibitors of stearoyl-coenzyme a delta-9 desaturase |
| TWI720517B (zh) | 2009-01-15 | 2021-03-01 | 美商英塞特公司 | 製造ｊａｋ抑制劑之方法及相關中間化合物 |
| EP2210890A1 (en) | 2009-01-19 | 2010-07-28 | Almirall, S.A. | Oxadiazole derivatives as S1P1 receptor agonists |
| US8263601B2 (en) | 2009-02-27 | 2012-09-11 | Concert Pharmaceuticals, Inc. | Deuterium substituted xanthine derivatives |
| SI2432472T1 (sl) | 2009-05-22 | 2019-11-29 | Incyte Holdings Corp | 3-(4-(7H-pirolo(2,3-d)pirimidin-4-il)-1H-pirazol-1-il)oktan- ali heptan-nitril kot inhibitorji JAK |
| AR076794A1 (es) | 2009-05-22 | 2011-07-06 | Incyte Corp | Derivados de n-(hetero)aril-pirrolidina de pirazol-4-il-pirrolo [2,3-d]pirimidinas y pirrol-3-il-pirrolo [2,3-d ]pirimidinas como inhibidores de la quinasa janus y composiciones farmaceuticas que los contienen |
| UA110324C2 (en) | 2009-07-02 | 2015-12-25 | Genentech Inc | Jak inhibitory compounds based on pyrazolo pyrimidine |
| WO2011003418A1 (en) | 2009-07-08 | 2011-01-13 | Leo Pharma A/S | Heterocyclic compounds as jak receptor and protein tyrosine kinase inhibitors |
| US20120157500A1 (en) | 2009-08-24 | 2012-06-21 | Weikang Tao | Jak inhibition blocks rna interference associated toxicities |
| TW201111385A (en) | 2009-08-27 | 2011-04-01 | Biocryst Pharm Inc | Heterocyclic compounds as janus kinase inhibitors |
| TW201113285A (en) | 2009-09-01 | 2011-04-16 | Incyte Corp | Heterocyclic derivatives of pyrazol-4-yl-pyrrolo[2,3-d]pyrimidines as janus kinase inhibitors |
| SG178986A1 (en) | 2009-09-08 | 2012-04-27 | Hoffmann La Roche | 4-substituted pyridin-3-yl-carboxamide compounds and methods of use |
| EP2305660A1 (en) | 2009-09-25 | 2011-04-06 | Almirall, S.A. | New thiadiazole derivatives |
| EA021478B1 (ru) | 2009-10-09 | 2015-06-30 | Инсайт Корпорейшн | ГИДРОКСИЛЬНЫЕ, КЕТО И ГЛЮКУРОНИДНЫЕ ПРОИЗВОДНЫЕ 3-(4-(7Н-ПИРРОЛО[2,3-d]ПИРИМИДИН-4-ИЛ)-1Н-ПИРАЗОЛ-1-ИЛ)-3-ЦИКЛОПЕНТИЛПРОПАННИТРИЛА |
| CA2775009A1 (en) | 2009-10-20 | 2011-04-28 | Cellzome Limited | Heterocyclyl pyrazolopyrimidine analogues as jak inhibitors |
| US20110113416A1 (en) | 2009-11-09 | 2011-05-12 | Bank Of America Corporation | Network-Enhanced Control Of Software Updates Received Via Removable Computer-Readable Medium |
| EP2332917B1 (en) | 2009-11-11 | 2012-08-01 | Sygnis Bioscience GmbH & Co. KG | Compounds for PIM kinase inhibition and for treating malignancy |
| CN102740888B (zh) | 2009-11-24 | 2016-10-12 | 奥尔德生物制药公司 | Il-6抗体及其用途 |
| WO2011069141A2 (en) | 2009-12-04 | 2011-06-09 | Board Of Regents, The University Of Texas System | Interferon therapies in combination with blockade of stat3 activation |
| WO2011075334A1 (en) | 2009-12-18 | 2011-06-23 | Pfizer Inc. | Pyrrolo[2,3-d]pyrimidine compounds |
| RU2012132278A (ru) | 2010-01-12 | 2014-02-20 | Ф. Хоффманн-Ля Рош Аг | Трициклические гетероциклические соединения, содержащие их композиции и способы их применения |
| MX2012009074A (es) | 2010-02-05 | 2012-08-23 | Pfizer | Compuestos de urea pirrolo [2, 3-d] pirimidina como inhibidores de janus quinasa. |
| SA111320200B1 (ar) | 2010-02-17 | 2014-02-16 | ديبيوفارم اس ايه | مركبات ثنائية الحلقة واستخداماتها كمثبطات c-src/jak مزدوجة |
| JP5858434B2 (ja) | 2010-02-18 | 2016-02-10 | インサイト・ホールディングス・コーポレイションＩｎｃｙｔｅ Ｈｏｌｄｉｎｇｓ Ｃｏｒｐｏｒａｔｉｏｎ | Ｊａｎｕｓキナーゼ阻害薬としてのシクロブタンおよびメチルシクロブタン誘導体 |
| EP3354652B1 (en) | 2010-03-10 | 2020-05-06 | Incyte Holdings Corporation | Piperidin-4-yl azetidine derivatives as jak1 inhibitors |
| KR20130094710A (ko) | 2010-04-14 | 2013-08-26 | 어레이 바이오파마 인크. | Ｊａｋ 키나아제의 억제제로서 5,7-치환된-이미다조［1,2-ｃ］피리미딘 |
| EP2390252A1 (en) | 2010-05-19 | 2011-11-30 | Almirall, S.A. | New pyrazole derivatives |
| PE20130216A1 (es) | 2010-05-21 | 2013-02-27 | Incyte Corp | Formulacion topica para un inhibidor de jak |
| WO2011156698A2 (en) | 2010-06-11 | 2011-12-15 | Abbott Laboratories | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUNDS |
| WO2012003457A1 (en) | 2010-07-01 | 2012-01-05 | Mtm Research Llc | Anti-fibroblastic fluorochemical emulsion therapies |
| EP2621489A1 (en) | 2010-09-30 | 2013-08-07 | Portola Pharmaceuticals, Inc. | Combinations of 4-(cyclopropylamino)-2-(4-(4-(ethylsulfonyl)piperazin-1-yl)phenylamino)pyrimidine-5-carboxamide and fludarabine |
| US9034884B2 (en) | 2010-11-19 | 2015-05-19 | Incyte Corporation | Heterocyclic-substituted pyrrolopyridines and pyrrolopyrimidines as JAK inhibitors |
| PE20140146A1 (es) | 2010-11-19 | 2014-02-06 | Incyte Corp | Derivados de pirrolopiridina y pirrolopirimidina sustituidos con ciclobutilo como inhibidores de jak |
| AU2011335882B2 (en) | 2010-12-03 | 2016-03-10 | Ym Biosciences Australia Pty Ltd | Treatment of JAK2-mediated conditions |
| ES2547916T3 (es) | 2011-02-18 | 2015-10-09 | Novartis Pharma Ag | Terapia de combinación de inhibidores de mTOR/JAK |
| CN102247368B (zh) | 2011-05-19 | 2013-05-29 | 安徽永生堂药业有限责任公司 | 一种复方阿伐斯汀缓释片及其制备方法 |
| CN102218042A (zh) | 2011-05-26 | 2011-10-19 | 青岛黄海制药有限责任公司 | 富马酸喹硫平组合物的缓释片剂及其制备方法 |
| CN103797010B (zh) | 2011-06-20 | 2016-02-24 | 因塞特控股公司 | 作为jak抑制剂的氮杂环丁烷基苯基、吡啶基或吡嗪基甲酰胺衍生物 |
| WO2013007765A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Fused tricyclic compounds for use as inhibitors of janus kinases |
| WO2013007768A1 (en) | 2011-07-13 | 2013-01-17 | F. Hoffmann-La Roche Ag | Tricyclic heterocyclic compounds, compositions and methods of use thereof as jak inhibitors |
| EP2741747A1 (en) | 2011-08-10 | 2014-06-18 | Novartis Pharma AG | JAK P13K/mTOR COMBINATION THERAPY |
| TW201313721A (zh) | 2011-08-18 | 2013-04-01 | Incyte Corp | 作為ｊａｋ抑制劑之環己基氮雜環丁烷衍生物 |
| UA111854C2 (uk) | 2011-09-07 | 2016-06-24 | Інсайт Холдінгс Корпорейшн | Способи і проміжні сполуки для отримання інгібіторів jak |
| TW201406761A (zh) | 2012-05-18 | 2014-02-16 | Incyte Corp | 做爲ｊａｋ抑制劑之哌啶基環丁基取代之吡咯并吡啶及吡咯并嘧啶衍生物 |
| US10155987B2 (en) | 2012-06-12 | 2018-12-18 | Dana-Farber Cancer Institute, Inc. | Methods of predicting resistance to JAK inhibitor therapy |
| HRP20250965T1 (hr) | 2012-06-15 | 2025-10-10 | Sun Pharmaceutical Industries, Inc. | Deuterirani derivati ruksolitiniba |
| US20150246043A1 (en) | 2012-07-27 | 2015-09-03 | Ratiopharm Gmbh | Oral dosage forms for modified release comprising ruxolitinib |
| CN102772384A (zh) | 2012-08-07 | 2012-11-14 | 四川百利药业有限责任公司 | 一种盐酸米诺环素缓释片及其制备方法 |
| US9573958B2 (en) | 2012-08-31 | 2017-02-21 | Principia Biopharma, Inc. | Benzimidazole derivatives as ITK inhibitors |
| TWI646099B (zh) | 2012-11-01 | 2019-01-01 | 英塞特控股公司 | 作爲ｊａｋ抑制劑之三環稠合噻吩衍生物 |
| PH12020551186B1 (en) | 2012-11-15 | 2024-03-20 | Incyte Holdings Corp | Sustained-release dosage forms of ruxolitinib |
| RS62867B1 (sr) | 2013-03-06 | 2022-02-28 | Incyte Holdings Corp | Postupci i intermedijeri za dobijanje inhibitora jak |
| HUE033587T2 (hu) | 2013-05-17 | 2017-12-28 | Incyte Corp | Bipirazol-származékok mint JAK inhibitorok |
| SMT202000315T1 (it) | 2013-08-07 | 2020-07-08 | Incyte Corp | Forme di dosaggio a rilascio prolungato per un inibitore di jak1 |
| CA2921568A1 (en) | 2013-08-20 | 2015-02-25 | Incyte Corporation | Survival benefit in patients with solid tumors with elevated c-reactive protein levels |
| KR20160136323A (ko) | 2014-02-28 | 2016-11-29 | 인사이트 코포레이션 | 골수형성이상증후군 치료용 jak1 억제제 |
| SI3129021T1 (sl) | 2014-04-08 | 2021-07-30 | Incyte Corporation | Zdravljenje malignosti B-celic s kombinacijo zaviralcev JAK in PI3K |
| MA39987A (fr) | 2014-04-30 | 2017-03-08 | Incyte Corp | Procédés de préparation d'un inhibiteur de jak1 et nouvelles formes associées |
| WO2015184087A2 (en) | 2014-05-28 | 2015-12-03 | Institute For Myeloma & Bone Cancer Research | Anti-cancer effects of jak2 inhibitors in combination with thalidomide derivatives and glucocorticoids |
| US9498467B2 (en) | 2014-05-30 | 2016-11-22 | Incyte Corporation | Treatment of chronic neutrophilic leukemia (CNL) and atypical chronic myeloid leukemia (aCML) by inhibitors of JAK1 |
| US10766900B2 (en) | 2017-12-29 | 2020-09-08 | Formosa Laboratories, Inc. | Baricitinib intermediate, method for forming Baricitinib intermediate, and method for preparing Baricitinib or pharmaceutically acceptable salt thereof |
| AU2020219797B2 (en) | 2019-02-06 | 2025-10-16 | Sun Pharmaceutical Industries, Inc. | Process for preparing enantiomerically enriched jak inhibitors |
-
2006
- 2006-12-12 SG SG10202003901UA patent/SG10202003901UA/en unknown
- 2006-12-12 TW TW095146502A patent/TWI410407B/zh active
- 2006-12-12 HU HUE11152730A patent/HUE030418T2/en unknown
- 2006-12-12 EP EP20206996.9A patent/EP3838903B1/en active Active
- 2006-12-12 SI SI200632133A patent/SI2455382T1/sl unknown
- 2006-12-12 CN CN201310058988.2A patent/CN103214483B/zh active Active
- 2006-12-12 RS RS20170047A patent/RS55576B1/sr unknown
- 2006-12-12 DK DK11152708.1T patent/DK2348023T5/da active
- 2006-12-12 RS RS20170081A patent/RS55634B1/sr unknown
- 2006-12-12 TW TW107113620A patent/TWI664182B/zh active
- 2006-12-12 EP EP16197502.4A patent/EP3184526B1/en active Active
- 2006-12-12 SG SG2012014957A patent/SG179430A1/en unknown
- 2006-12-12 TW TW105120803A patent/TWI630207B/zh active
- 2006-12-12 MY MYPI20082099A patent/MY159449A/en unknown
- 2006-12-12 WO PCT/US2006/047369 patent/WO2007070514A1/en not_active Ceased
- 2006-12-12 KR KR1020127024525A patent/KR101391900B1/ko active Active
- 2006-12-12 PL PL11152708T patent/PL2348023T3/pl unknown
- 2006-12-12 DK DK11152677.8T patent/DK2343299T3/en active
- 2006-12-12 EA EA200870048A patent/EA019504B1/ru active Protection Beyond IP Right Term
- 2006-12-12 CN CN201310059187.8A patent/CN103214484B/zh active Active
- 2006-12-12 AT AT06839328T patent/ATE525374T1/de active
- 2006-12-12 EP EP11152714.9A patent/EP2474545B1/en active Active
- 2006-12-12 PL PL11152714T patent/PL2474545T3/pl unknown
- 2006-12-12 RS RS20181405A patent/RS58113B1/sr unknown
- 2006-12-12 AU AU2006326548A patent/AU2006326548B2/en active Active
- 2006-12-12 LT LTEP11152723.0T patent/LT2426129T/lt unknown
- 2006-12-12 SI SI200632135A patent/SI2426129T1/sl unknown
- 2006-12-12 KR KR1020127024523A patent/KR101324737B1/ko active Active
- 2006-12-12 ES ES11152677.8T patent/ES2561507T3/es active Active
- 2006-12-12 DK DK11152723.0T patent/DK2426129T3/en active
- 2006-12-12 HU HUE11152723A patent/HUE030235T2/en unknown
- 2006-12-12 RS RS20170079A patent/RS55632B1/sr unknown
- 2006-12-12 HU HUE11152714A patent/HUE032337T2/en unknown
- 2006-12-12 EP EP11152674.5A patent/EP2343298B9/en active Active
- 2006-12-12 HU HUE11152708A patent/HUE025173T2/hu unknown
- 2006-12-12 ES ES11152674.5T patent/ES2543903T3/es active Active
- 2006-12-12 EP EP11152730.5A patent/EP2455382B1/en active Active
- 2006-12-12 ES ES18191992T patent/ES2867505T3/es active Active
- 2006-12-12 EP EP06839328A patent/EP1966202B1/en active Active
- 2006-12-12 PL PL06839328T patent/PL1966202T3/pl unknown
- 2006-12-12 ES ES11152708.1T patent/ES2543904T3/es active Active
- 2006-12-12 US US11/637,545 patent/US7598257B2/en active Active
- 2006-12-12 SI SI200632020A patent/SI2343299T1/sl unknown
- 2006-12-12 EA EA201200132A patent/EA035795B1/ru active Protection Beyond IP Right Term
- 2006-12-12 PT PT111527305T patent/PT2455382T/pt unknown
- 2006-12-12 HU HUE11152677A patent/HUE028588T2/hu unknown
- 2006-12-12 MX MX2015003466A patent/MX346183B/es unknown
- 2006-12-12 EP EP11152723.0A patent/EP2426129B1/en active Active
- 2006-12-12 CN CN201310058991.4A patent/CN103254190B/zh active Active
- 2006-12-12 ES ES06839328T patent/ES2373688T3/es active Active
- 2006-12-12 SG SG10201506912RA patent/SG10201506912RA/en unknown
- 2006-12-12 TW TW103136068A patent/TWI553008B/zh active
- 2006-12-12 TW TW103117669A patent/TW201434835A/zh unknown
- 2006-12-12 ES ES11152723.0T patent/ES2612196T3/es active Active
- 2006-12-12 MY MYPI2013002970A patent/MY162590A/en unknown
- 2006-12-12 SI SI200632294T patent/SI3184526T1/sl unknown
- 2006-12-12 DK DK11152730.5T patent/DK2455382T3/da active
- 2006-12-12 UA UAA200809072A patent/UA98449C2/ru unknown
- 2006-12-12 NZ NZ569015A patent/NZ569015A/en unknown
- 2006-12-12 PL PL11152730T patent/PL2455382T3/pl unknown
- 2006-12-12 PT PT111527230T patent/PT2426129T/pt unknown
- 2006-12-12 ES ES11152730.5T patent/ES2611588T3/es active Active
- 2006-12-12 EP EP18191992.9A patent/EP3466953B1/en active Active
- 2006-12-12 PT PT111527081T patent/PT2348023E/pt unknown
- 2006-12-12 PT PT06839328T patent/PT1966202E/pt unknown
- 2006-12-12 TW TW101121442A patent/TWI468162B/zh active
- 2006-12-12 JP JP2008545733A patent/JP5017278B2/ja active Active
- 2006-12-12 HU HUE16197502A patent/HUE041382T2/hu unknown
- 2006-12-12 PL PL16197502T patent/PL3184526T3/pl unknown
- 2006-12-12 EA EA201691294A patent/EA036785B1/ru active Protection Beyond IP Right Term
- 2006-12-12 NZ NZ778831A patent/NZ778831A/en unknown
- 2006-12-12 RS RS20160052A patent/RS54683B1/sr unknown
- 2006-12-12 ES ES16197502T patent/ES2700433T3/es active Active
- 2006-12-12 UA UAA201115478A patent/UA116187C2/uk unknown
- 2006-12-12 HR HR20110903T patent/HRP20110903T1/hr unknown
- 2006-12-12 KR KR1020117029741A patent/KR101218214B1/ko active Active
- 2006-12-12 PT PT111526778T patent/PT2343299E/pt unknown
- 2006-12-12 ES ES20206996T patent/ES2970354T3/es active Active
- 2006-12-12 RS RS20110571A patent/RS52101B/sr unknown
- 2006-12-12 DK DK06839328.9T patent/DK1966202T3/da active
- 2006-12-12 PL PL11152677.8T patent/PL2343299T3/pl unknown
- 2006-12-12 CN CNA2006800527507A patent/CN101448826A/zh not_active Withdrawn
- 2006-12-12 DK DK16197502.4T patent/DK3184526T3/en active
- 2006-12-12 RS RS20150513A patent/RS54181B9/sr unknown
- 2006-12-12 PL PL11152723T patent/PL2426129T3/pl unknown
- 2006-12-12 ES ES11152714.9T patent/ES2612489T3/es active Active
- 2006-12-12 LT LTEP11152714.9T patent/LT2474545T/lt unknown
- 2006-12-12 LT LTEP11152730.5T patent/LT2455382T/lt unknown
- 2006-12-12 EP EP11152708.1A patent/EP2348023B9/en active Active
- 2006-12-12 SI SI200632137A patent/SI2474545T1/sl unknown
- 2006-12-12 EP EP11152677.8A patent/EP2343299B9/en active Active
- 2006-12-12 SI SI200631956T patent/SI2348023T1/sl unknown
- 2006-12-12 DK DK11152714.9T patent/DK2474545T3/en active
- 2006-12-12 SI SI200631209T patent/SI1966202T1/sl unknown
- 2006-12-12 PT PT111527149T patent/PT2474545T/pt unknown
- 2006-12-12 BR BRPI0619817A patent/BRPI0619817B8/pt active IP Right Grant
- 2006-12-12 ME MEP-2011-199A patent/ME01312B/me unknown
- 2006-12-12 PT PT16197502T patent/PT3184526T/pt unknown
- 2006-12-12 LT LTEP16197502.4T patent/LT3184526T/lt unknown
- 2006-12-12 CA CA2632466A patent/CA2632466C/en active Active
- 2006-12-13 AR ARP060105499A patent/AR057995A1/es active IP Right Grant
-
2008
- 2008-06-05 IL IL192019A patent/IL192019A/en active IP Right Grant
- 2008-06-12 ZA ZA2008/05165A patent/ZA200805165B/en unknown
- 2008-06-12 CR CR10065A patent/CR10065A/es unknown
- 2008-06-12 US US12/138,082 patent/US8415362B2/en active Active
- 2008-06-13 EC EC2008008540A patent/ECSP088540A/es unknown
- 2008-07-11 KR KR1020087017011A patent/KR101216055B1/ko active Active
-
2009
- 2009-08-27 US US12/549,170 patent/US8541425B2/en active Active
-
2011
- 2011-03-30 US US13/076,176 patent/US8946245B2/en active Active
- 2011-03-30 US US13/076,220 patent/US8530485B2/en active Active
- 2011-09-05 JP JP2011192962A patent/JP5710430B2/ja active Active
- 2011-12-20 CY CY20111101270T patent/CY1112762T1/el unknown
-
2012
- 2012-03-08 EC ECSP12008540 patent/ECSP12008540A/es unknown
-
2013
- 2013-01-09 LT LTPA2013002C patent/LTPA2013002I1/lt unknown
- 2013-01-18 LU LU92137C patent/LU92137I2/fr unknown
- 2013-01-21 FR FR13C0007C patent/FR13C0007I2/fr active Active
- 2013-02-15 CY CY2013006C patent/CY2013006I1/el unknown
- 2013-02-19 BE BE2013C014C patent/BE2013C014I2/fr unknown
- 2013-09-06 US US14/020,505 patent/US9206187B2/en active Active
- 2013-09-20 US US14/033,039 patent/US8933086B2/en active Active
- 2013-10-03 CR CR20130506A patent/CR20130506A/es unknown
- 2013-12-17 JP JP2013260480A patent/JP5876026B2/ja active Active
-
2014
- 2014-04-08 IL IL231992A patent/IL231992A/en active IP Right Grant
- 2014-05-12 US US14/274,948 patent/US9079912B2/en active Active
-
2015
- 2015-05-13 US US14/711,576 patent/US20150238492A1/en not_active Abandoned
- 2015-07-06 JP JP2015135307A patent/JP6138865B2/ja active Active
- 2015-07-31 CY CY20151100673T patent/CY1116574T1/el unknown
- 2015-08-06 HR HRP20150837TT patent/HRP20150837T2/hr unknown
-
2016
- 2016-02-02 HR HRP20160112TT patent/HRP20160112T1/hr unknown
- 2016-06-03 US US15/173,057 patent/US9662335B2/en active Active
- 2016-08-10 US US15/233,652 patent/US9814722B2/en active Active
- 2016-11-13 IL IL248938A patent/IL248938A0/en unknown
- 2016-11-21 US US15/356,957 patent/US9974790B2/en active Active
-
2017
- 2017-01-19 HR HRP20170090TT patent/HRP20170090T1/hr unknown
- 2017-01-20 CY CY20171100089T patent/CY1118506T1/el unknown
- 2017-01-30 CY CY20171100130T patent/CY1118724T1/el unknown
- 2017-02-01 HR HRP20170162TT patent/HRP20170162T1/hr unknown
- 2017-02-07 HR HRP20170200TT patent/HRP20170200T1/hr unknown
- 2017-02-08 CY CY20171100171T patent/CY1118607T1/el unknown
- 2017-04-25 FR FR17C1013C patent/FR17C1013I2/fr active Active
- 2017-04-25 LT LTPA2017012C patent/LTPA2017012I1/lt unknown
- 2017-04-25 HU HUS1700017C patent/HUS1700017I1/hu unknown
- 2017-04-25 CY CY2017015C patent/CY2017015I1/el unknown
-
2018
- 2018-04-23 US US15/960,069 patent/US10398699B2/en active Active
- 2018-11-01 US US16/177,602 patent/US10639310B2/en active Active
- 2018-11-16 HR HRP20181912TT patent/HRP20181912T1/hr unknown
- 2018-12-27 CY CY20181101401T patent/CY1121202T1/el unknown
-
2020
- 2020-03-17 US US16/821,624 patent/US11331320B2/en active Active
-
2022
- 2022-03-08 US US17/689,510 patent/US11744832B2/en active Active
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| UA116187C2 (uk) | ГЕТЕРОАРИЛЗАМІЩЕНІ ПІРОЛО[2,3-b]ПІРИДИНИ Й ПІРОЛО[2,3-b]ПІРИМІДИНИ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ | |
| UA104849C2 (uk) | 4-піразоліл-n-арилпіримідин-2-аміни і 4-піразоліл-n-гетероарилпіримідин-2-аміни як інгібітори кіназ janus | |
| TW200634010A (en) | Pyrrolo[2,3-b]pyridin-4-yl-amines and pyrrolo[2,3-b]pyrimidin-4-yl-amines as janus kinase inhibitors | |
| MX2009006162A (es) | Compuestos y metodos para modulacion de cinasas, e indicaciones para ello. | |
| MX2009006688A (es) | Compuestos y metodos para modulacion de cinasas, e indicaciones para ello. | |
| CY1115145T1 (el) | Αλατα του αναστολεα κινασης janus (r)-3-(4-(7h-πyppoλo[2,3-d]πυριμιδιν-4-υλ)-1η-πυραζολ-1-υλ)-3-κυκλοπεντυλο-προπανονιτριλιου | |
| MX2009012623A (es) | Moduladores de cinasa heterociclicos. | |
| EA200970402A1 (ru) | Триазолопиридазиновые модуляторы протеинкиназ | |
| WO2008080134A3 (en) | 4-amin0-2- (hetero) arylamino-5- (hetero) arylthiazoles useful as axl inhibitors | |
| ATE517901T1 (de) | Pyrazolopyrimidine als hemmer der proteinkinase b (akt) | |
| MX2008001538A (es) | Aril piridinas y metodos para su uso. | |
| ATE373658T1 (de) | Pyrazoloisoquinolinenderivaten zur inhibierung von nfkappab-induzierende kinase | |
| EA202091617A1 (ru) | Гетероарил-замещенные пирроло[2,3-b]пиридины и пирроло[2,3-b]пиримидины в качестве ингибиторов янус-киназы | |
| TW200801020A (en) | Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines | |
| UA106617C2 (uk) | N-(ГЕТЕРО)АРИЛПІРОЛІДИНОВІ ПОХІДНІ ПІРАЗОЛ-4-ІЛПІРОЛО[2,3-d]ПІРИМІДИНІВ І ПІРОЛ-3-ІЛПІРОЛО[2,3-d]ПІРИМІДИНІВ ЯК ІНГІБІТОРИ ЯНУС-КІНАЗИ | |
| CY1117389T1 (el) | ΕΤΕΡΟΑΡΥΛΟ ΥΠΟΚΑΤΕΣΤΗΜΕΝΕΣ ΠΥΡΡΟΛΟ[2,3-b] ΠΥΡΙΔΙΝΕΣ ΚΑΙ ΠΥΡΡΟΛΟ[2,3-b]ΠΥΡΙΜΙΔΙΝΕΣ ΩΣ ΑΝΑΣΤΟΛΕΙΣ ΚΙΝΑΣΗΣ JANUS | |
| WO2007026221A3 (en) | Improved methods for preparing benzofused heteroaryl amide derivatives of thienopyridines | |
| HK1157330A (en) | 5h-pyrr0l0 [2,3-b]pyrazine derivatives for kinase modulation, and indications therefor |